# THE ROLE OF $K^+$ CHANNELS IN CELL PROLIFERATION AND CELL VOLUME REGULATION IN HUMAN BRONCHIAL EPITHELIAL CELLS

by

Katie M. MacLeod

Submitted in partial fulfilment of the requirements for the degree of Master of Science

at

Dalhousie University Halifax, Nova Scotia August 2011

© Copyright by Katie M. MacLeod, 2011

#### DALHOUSIE UNIVERSITY

#### DEPARTMENT OF PHYSIOLOGY AND BIOPHYSICS

The undersigned hereby certify that they have read and recommend to the Faculty of Graduate Studies for acceptance a thesis entitled "THE ROLE OF K<sup>+</sup> CHANNELS IN CELL PROLIFERATION AND CELL VOLUME REGULATION IN HUMAN BRONCHIAL EPITHELIAL CELLS" by Katie M. MacLeod in partial fulfilment of the requirements for the degree of Master of Science.

	Dated	:	August 5, 2011
Supervisor:	_		
Readers:	_		
	-		
	_		
	_		
Departmental Representative:			

# DALHOUSIE UNIVERSITY

		DATE:	August 5, 20	)11	
AUTHOR:	Katie M. MacLeod	I			
TITLE:		† CHANNELS IN CE REGULATION IN H LLS			ND
DEPARTMENT OR SCHOOL: Department of Physiology and Biophysics					
DEGREE:	MSc	CONVOCATION:	October	YEAR:	2011
Permission is herewith granted to Dalhousie University to circulate and to have copied for non-commercial purposes, at its discretion, the above title upon the request of individuals or institutions. I understand that my thesis will be electronically available to the public.					
The author reserves other publication rights, and neither the thesis nor extensive extracts from it may be printed or otherwise reproduced without the author's written permission.					
The author attests that permission has been obtained for the use of any copyrighted material appearing in the thesis (other than the brief excerpts requiring only proper acknowledgement in scholarly writing), and that all such use is clearly acknowledged.					
		Signatur	re of Author		

# **TABLE OF CONTENTS**

LIST O	F TABLES	Vii
LIST O	F FIGURES	viii
ABSTR	ACT	ix
LIST C	F ABBREVIATIONS AND SYMBOLS USED	X
ACKNO	DWLEGEMENTS	xiii
СНАРТ	ER 1: INTRODUCTION	1
1.1	EPITHELIAL CELL PHYSIOLOGY	1
1.2	ION CHANNELS IN THE AIRWAYS AND CYSTIC FIBROSIS	2
1.3	K <sup>+</sup> CHANNELS IN EPITHELIAL CELL PHYSIOLOGY	3
1.4	VOLTAGE-GATED (K <sub>v</sub> ) K <sup>+</sup> CHANNELS	4
1	.4.1 K <sub>v</sub> 7.1 AND 7.5	5
1	.4.2 K <sub>v</sub> 4.1, 4.2 AND 4.3	6
1	.4.3 K <sub>v</sub> 10.1 AND 11.1	7
1.5	CALCIUM-ACTIVATED (K <sub>Ca</sub> ) K <sup>+</sup> CHANNELS	8
1	.5.1 K <sub>Ca</sub> 1.1	8
1	.5.2 K <sub>Ca</sub> 3.1	9
1.6	K <sup>+</sup> CHANNELS IN CELL PROLIFERATION	9
1.7	K <sup>+</sup> CHANNELS IN CELL VOLUME REGULATION	11
1.8	16HBE14o- AND CFBE41o- CELLS AS MODEL CELL LINES	12
1.9	STUDY OBJECTIVES	12
CHAP	TER 2: MATERIALS AND METHODS	18
2.1	CELL CULTURE	18
2.2	CELL COUNTING	19
2.3	LACTATE DEHYDROGENASE (LDH) CYTOTOXICITY ASSAY	19
2.4	RNA EXTRACTION	20
2.5	REVERSE TRANSCRIPTION OF RNA TO SINGLE STRANDED cDNA	21
2.6	POLYMERASE CHAIN REACTION (PCR)	21
2.7	AGAROSE GEL ELECTROPHORESIS	22

2.8	WESTERN BLOTTING	22
2.9	CELL VOLUME REGULATION	23
2.10	siRNA TRANSFECTION	24
2.11	PLASMID DNA TRANSFECTION	25
2.12	DRUGS	26
2.13	STATISTICS	26
CHAPT	ER 3: RESULTS	27
3.1	HBE AND CFBE CELLS EXPRESS K <sub>v</sub> AND K <sub>Ca</sub> CHANNEL mRNA	27
3.2	HBE AND CFBE CELLS EXPRESS $K_v7.1$ AND $K_v7.5$ PROTEIN	27
3.3	VARIOUS K <sub>v</sub> AND K <sub>Ca</sub> CHANNEL INHIBITORS AFFECT CELL PROLIFERATION IN HBE AND CFBE CELLS	27
3.4	CELL PROLIFERATION IS NOT AFFECTED BY THE ADDITION OF THE POTENTIAL MITOGENS EGF, IGF-1 OR E2	29
3.5	CELL PROLIFERATION IS NOT AFFECTED BY THE ADDITION OF THE POTENTIAL $K_{\nu}7$ CHANNEL ACTIVATOR FLUPIRTINE MALEATE	30
3.6	HBE CELLS EXHIBIT AN RVD RESPONSE WHEN EXPOSED TO HYPOSMOTIC SOLUTIONS	30
3.7	VARIOUS PHARMACOLOGICAL $K_{\nu}$ AND $K_{Ca}$ CHANNEL INHIBITORS AFFECT THE RVD RESPONSE IN HBE CELLS	31
3.8	$\ensuremath{K_{v}} 7.1$ Channels affect the RVD response in Hbe cells	32
3.9	CFBE CELLS DO NOT ELICIT AN RVD RESPONSE WHEN EXPOSED TO HYPOSMOTIC STRESS	33
3.10	HBE AND CFBE CELLS DO NOT ELICIT AN RVI RESPONSE WHEN EXPOSED TO HYPEROSMOTIC SOLUTIONS	33
CHAPT	ER 4: DISCUSSION	54
4.1	EXPRESSION OF $K^{\scriptscriptstyle +}$ CHANNELS IN HBE AND CFBE CELLS	55
4.2	THE ACTIVITY OF K <sup>+</sup> CHANNELS IN HBE AND CFBE BASAL CELL PROLIFERATION	56
4.	2.1 THE ROLE OF K <sub>v</sub> 7 CHANNELS IN HBE AND CFBE CELL PROLIFERATION	57
4.	2.2 THE ROLE OF K <sub>v</sub> 4, K <sub>v</sub> 10 AND K <sub>v</sub> 11 CHANNELS IN HBE AND CFBE CELL PROLIFERATION	58
4.	2.3 THE ROLE OF K <sub>Ca</sub> 1.1 AND K <sub>Ca</sub> 3.1 CHANNELS IN HBE AND	60

4.2.4 LIMITATIONS IN THE SELECTIVITY OF K <sup>+</sup> CHANNELS FOR CELL PROLIFERATION STUDIES	60
4.2.5 PROPOSED MECHANISM FOR THE ROLE OF K <sup>+</sup> CHANNELS IN CELL PROLIFERATION IN AIRWAY EPITHELIAL CELLS	61
4.3 THE ACTIVITY OF K <sup>+</sup> CHANNELS IN MITOGENIC- AND ACTIVATOR-STIMULATED CELL PROLIFERATION	62
4.3.1 THE ROLE OF MITOGEN-STIMULATED CELL PROLIFERATION IN HBE AND CFBE CELLS	62
4.3.2 THE ROLE OF K <sub>v</sub> 7 CHANNEL ACTIVATOR-STIMULATED CELL PROLIFERATION IN HBE AND CFBE CELLS	63
4.4 THE ACTIVITY OF K <sup>+</sup> CHANNELS IN THE REGULATION OF HBE CELL VOLUME IN TIMES OF HYPOSMOTIC STRESS	64
4.4.1 THE ROLE OF $K_v$ 7 CHANNELS IN HBE CELL VOLUME REGULATION	65
4.4.2 THE ROLE OF K <sub>v</sub> 4, K <sub>v</sub> 10 AND K <sub>v</sub> 11 CHANNELS IN HBE CELL VOLUME REGULATION	66
4.4.3 THE ROLE OF K <sub>Ca</sub> 1.1 AND K <sub>Ca</sub> 3.1 CHANNELS IN HBE CELL VOLUME REGULATION	67
4.4.4 LIMITATIONS IN THE STUDY OF K <sup>+</sup> CHANNELS AND THE RVD RESPONSE IN HBE CELLS	68
4.4.5 PROPOSED MECHANISM FOR THE ROLE OF K <sup>+</sup> CHANNELS IN CELL VOLUME REGULATION AND THE RVD RESPONSE IN HBE CELLS	68
4.5 THE REGULATION OF CFBE CELL VOLUME IN TIMES OF HYPOSMOTIC STRESS	69
4.6 THE REGULATION OF HBE AND CFBE CELL VOLUME IN TIMES OF HYPEROSMOTIC STRESS	71
4.7 THE SIGNIFICANCE OF K <sup>+</sup> CHANNEL ACTIVITY IN CELL PROLIFERATION AND CELL VOLUME REGULATION IN RESPIRATORY EPITHELIAL PHYSIOLOGY	71
REFERENCES	
APPENDIX A: TABLES	88
APPENDIX B: RECIPES	92

# LIST OF TABLES

Table 1. K <sup>+</sup> channel name and their corresponding gene name	88
Table 2. K <sup>+</sup> channel inhibitors and information	89
Table 3. PCR primer sequences and information	90
Table 4. Antibody information	91

# LIST OF FIGURES

Figure 1. Representative model cells	of ion and fluid transport in airway epithelial	14
Figure 2. Structural model of v	rarious types of K <sup>+</sup> channels	16
Figure 3. Schematic representa	tion of the cell cycle	.17
-	mRNA transcripts are expressed in HBE and	35
Figure 5. $K_v7.1$ and $K_v7.5$ prote	ein are expressed in HBE and CFBE cells	36
Figure 6. Cell doubling time for	or HBE and CFBE cells	37
Figure 7. Contribution of K <sup>+</sup> ch	nannels to cell proliferation in HBE and CFBE cells	38
Figure 8. Cell viability followi	ng treatment with K <sup>+</sup> channel inhibitors	40
Figure 9. The mitogens EGF, Io in HBE and CFBE co	GF-1 and E2 have no effect on cell proliferation ells	.42
	etivator flupirtine maleate does not affect cell E and CFBE cells	44
C	esponse to hyposmotic shock and then undergo RVD depending on the osmolarity	45
Figure 12. Contribution of vari	ous K <sup>+</sup> channels to the RVD response in HBE cells	47
Figure 13. K <sub>v</sub> 7.1, K <sub>v</sub> 11.1, K <sub>Ca</sub> 1 HBE cells	.1 and K <sub>Ca</sub> 3.1 play a role in the RVD response in	.48
	NA did not suppress K <sup>+</sup> channel protein in	49
	the RVD response in HBE cells by pharmacological	50
Figure 16. K <sub>v</sub> 7.1 plays a role in	the RVD response in HBE cells by molecular means .	51
	ndergo a significant RVD response when exposed of hyposmotic stress	52
	s do not undergo a RVI response when exposed to syperosmotic stress	53
	ustrating the mechanisms involved in K <sup>+</sup> channel eration in HBE and CFBE cells	73
	ustrating the mechanisms involved in K <sup>+</sup> channel ne regulation in HBE cells	74

#### **ABSTRACT**

 $K^+$  channels are expressed in a wide variety of cell types, including airway epithelial cells. The purpose of this study was to investigate the role of various  $K_v$  and  $K_{Ca}$  channels in cell proliferation and cell volume regulation in HBE and CFBE cell lines. Methods included mRNA and protein detection, cell counting and cytotoxicity assays, and cell volume experiments. HBE and CFBE cells expressed many  $K^+$  channel mRNA and protein, including  $K_v7.1$ ,  $K_v7.5$ ,  $K_v4.1$ ,  $K_v4.2$ ,  $K_v10.1$ ,  $K_v11.1$ ,  $K_{Ca}1.1$  and  $K_{Ca}3.1$ . Various  $K_v$  and  $K_{Ca}$  channels played a role in HBE and CFBE basal cell proliferation, as well as in mediating the regulatory volume decrease (RVD) response in HBE cells. CFBE cells did not elicit an RVD response and neither cell line underwent a regulatory volume increase (RVI) response. Therefore,  $K^+$  channels play an important role in cell proliferation and the regulation of cell volume in bronchial epithelial physiology.

#### LIST OF ABBREVIATIONS AND SYMBOLS USED

ASL airway surface liquid

 $\begin{array}{lll} \alpha & & \text{alpha} \\ \text{NH}_2 & & \text{amino} \\ \text{bp} & & \text{base pair} \\ \beta & & \text{beta} \end{array}$ 

HCO<sub>3</sub> bicarbonate

K<sub>Ca</sub> calcium-activated potassium channel

CaM calmodulin
COOH carboxyl
°C celsius
cm centimeters

CNS central nervous system

CFBE CFBE41o-Cl chloride

cDNA complementary deoxyribonucleic acid

[C] concentration

cAMP cyclic adenosine monophosphate

CF cystic fibrosis

CFTR cystic fibrosis transmembrane conductance regulator gene

dNTP deoxyribonucleoside triphosphate

DMSO dimethyl sulfoxide S DNA synthesis

elk eag-like erg eag-related

EGFP enhanced green fluorescent protein

EGF epidermal growth factor

EGF-R epidermal growth factor receptor

ENaC epithelial Na<sup>+</sup> channel

Ε2 17β-estradiol eag ether-a-go-go

EBIO 1-ethyl-2-benzimidazolinone EDTA ethylenediaminetetraacetic acid

FBS fetal bovine serum

 $G_1$  first gap

GFG glycine-phenylalanine-glycine
GYG glycine-tyrosine-glycine

g gram

IC<sub>50</sub> half maximal inhibitory concentration

HBE 16HBE14ohr hours

hyper hyperosmotic hypo hyposmotic

IGF-1 insulin-like growth factor-1

 $\begin{array}{lll} IGF-1R & insulin-like growth factor-1 \ receptor \\ [Ca^{2^+}]_i & intracellular \ calcium \ concentration \\ [K^+]_i & intracellular \ potassium \ concentration \\ [Na^+]_i & intracellular \ sodium \ concentration \\ K_{ir} & inward-rectified \ potassium \ channel \\ \end{array}$ 

INT 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl tetrazolium

iso isosmotic kDa kilodaltons

LDH lactate dehydrogenase

L litres

mRNA messenger ribonucleic acid

 $\begin{array}{ccc} m & & meters \\ \mu & & micro, 10^{-6} \\ m & & mili, 10^{-3} \end{array}$ 

MEM Minimum Essential Media

min minutes M mitosis M molar mol mole

M-MLV Moloney Murine Leukemia Virus

MCC mucociliary clearance M-type muscarine sensitive

I<sub>m</sub> muscarine sensitive potassium current

n nano,  $10^{-9}$ 

Opti-MEM Reduced Serum Media

% percent

PCL perciliary liquid layer

PMSF phenylmethanesulfonyl fluoride  $4\alpha$ -PDD  $4\alpha$ -phorbol 12, 13-didecanoate PBS phosphate buffered saline PCR polymerase chain reaction  $K_2P$  2-pore potassium channel

K<sup>+</sup> potassium

KCC potassium/chloride co-transporter

1° primary

I<sub>Kr</sub> rapid delayed rectifier potassium current

RVD regulatory volume decrease
RVI regulatory volume increase
RCF relative centrifugal force
RT reverse transcription
RPM revolutions per minute

 $2^{\circ}$  secondary s seconds  $G_2$  second gap

I<sub>Ks</sub> slow delayed rectifier potassium current

siRNA small interfering ribonucleic acid

Na<sup>+</sup> sodium

SDS sodium dodecyl sulphate SEM standard error of the mean

t time

I<sub>A</sub> transient outward A-type potassium current

I<sub>to</sub> transient outward potassium current

TMDs transmembrane domains

TBS Tris-base saline

TBS-T Tris-base saline with Tween

TBE Tris/Borate/EDTA

U units

 $^{\mathrm{v}}\!/_{\mathrm{v}}$  volume to volume

K<sub>v</sub> voltage-dependent potassium channel

V volts  $H_2O$  water

#### **ACKNOWLEDGEMENTS**

I would first like to thank my supervisor, Dr. Elizabeth Cowley for all her expertise, guidance and continuous support over the last few years. Without her, I would not be where I am today.

I would also like to thank the members of my supervisory and examining committees for all their expertise, guidance, and time:

Dr. Paul Linsdell

Dr. Robert Rose

Dr. Nikolas Morgunov

Dr. Jonathan Blay

Dr. Boris Kablar

Dr. Paul Murphy (Chair)

I would like to thank the following people for their expertise, technical support, training and unconditional support:

Christina Jones

Emma Kalbfleisch

Yassine El-Hiani

Tiesong Li

Steven Broadbent

Mansong Li

Feng Qian

Wuyang Wang

Jeremy Roy

Brian Hoyt

Stephen Whitefield

All the graduate students in the department of Physiology and Biophysics

Finally, I would like to thank my family and friends for all their love and support over the last few years.

#### **CHAPTER 1: INTRODUCTION**

#### 1.1 Epithelial cell physiology

Epithelial cells line various organs in the human body and are involved in many physiological functions, including barrier formation and the regulation of body fluid composition and volume through ion transport (Wills *et al.*, 1996). These mechanisms require epithelial cells to have two very important properties, which are characteristic to all types of epithelial cells; firstly, the fact that they have tight junctions, and secondly, their ability to be polarized, which means they have transport proteins asymmetrically distributed between their apical and basolateral membranes (Wills *et al.*, 1996). The tight junctions are essential for the barrier role that epithelial cells play, because they allow the cell to control the passage of not only fluids, but also ions and other solutes between adjoining cells, creating a route of transport between two neighbouring cells known as the paracellular pathway (Wills *et al.*, 1996). Due to the polarization of epithelial cells, they are able to transport ions and fluids in order to regulate the composition and volume of body fluids (Muth and Caplan, 2003). These characteristics allow for the transepithelial transport of ions and fluids, one of the most studied aspects of epithelial cell physiology. (Muth and Caplan, 2003).

In the airways, and more specifically the bronchi, epithelial cells not only play a role in barrier formation and ion transport, but also in defense mechanisms such as mucociliary clearance (MCC) and innate host defense, as well as in physiological processes like wound repair, cell proliferation and cell volume regulation (Wills *et al.*, 1996; Chilvers and O'Callaghan, 2000; Trinh *et al.*, 2007). Since the respiratory system is continuously exposed to the external environment, airway epithelial cells develop defense mechanisms in order to protect the lungs from inhaled pathogens and infection. The main line of defense in the bronchi is MCC, where apically located cilia that line the epithelium physically get rid of any unwanted material (Chilvers and O'Callaghan, 2000). The bronchial epithelial cells are covered with airway surface liquid (ASL), that contains a heavier top mucus layer that traps pathogens that have been inhaled into the airways, and a more liquid lower layer known as the periciliary liquid layer (PCL), that bathes the cilia and allows them to beat properly and in an orderly fashion. During MCC,

the cilia beat in a coordinated manner and move the mucus layer of the ASL to the pharynx so it can either be swallowed or coughed out (Sleigh *et al.*, 1988). Bronchial epithelial cells also play a role in innate host defense, since they have the ability to release immunoglobins and other antimicrobial agents into the secretions that line the airways, and thus protect the lungs against infection (Gerritsen, 2000). In order for MCC to function properly and keep the lungs healthy and clean, the PCL volume must be closely regulated by ion and fluid transport (Blouquit-Laye and Chinet, 2007). Therefore, as mentioned above, one of the main functions of epithelial cells in the airways, and probably the most studied, is their ability to control the ionic composition and volume of fluids at the surface of the airways, also known as the transepithelial transport of ions and liquids. A classical example of a dysfunction in this transport mechanism is seen in the disease cystic fibrosis (CF).

#### 1.2 Ion channels in the airways and cystic fibrosis

The level of ASL in normal airway epithelial cells allowing for MCC is maintained by a balance between sodium (Na<sup>+</sup>) absorption and chloride (Cl<sup>-</sup>) secretion. This balance creates an adequate PCL volume, which allows for proper transport of ions and fluid, and keeps the lungs healthy via effective MCC. In the airways of an individual suffering from CF, the balance between Cl secretion and Na absorption is offset and causes a reduction of the PCL volume and an increase in sticky, dehydrated mucus (Bardou et al., 2009). CF is caused by a mutation in the cystic fibrosis transmembrane conductance regulator gene (CFTR), which encodes an apically located Cl channel that shares the same name (Kerem et al., 1989). To date, there are over 1,800 different CFcausing CFTR mutations; however the most common is the  $\Delta$ F508 mutation (Cystic Fibrosis Canada, 2011). This mutation is a three base pair (bp) deletion that omits a phenylalanine amino acid from position 508 on chromosome 7 and causes the CFTR protein to improperly fold and degrade before it is transported to the cell membrane (Ward et al., 1995). Because CFTR accounts for the majority of anion secretion in airway epithelial cells, mutations in this gene decrease these secretions, including Cl<sup>-</sup> and bicarbonate (HCO<sub>3</sub><sup>-</sup>), and increase the absorption of Na<sup>+</sup> ions through the apical epithelial Na<sup>+</sup> channel (ENaC), in turn disrupting the ionic balance (Gadsby *et al.*, 2006).

The CFTR protein is expressed on the apical surface of many epithelial cells, including those in the nose, colon, and lungs (Riordan *et al.*, 1989). In the lungs, most of the CFTR is expressed in the serous cells of the submucosal glands; however, there is expression of this protein in the surface epithelium that lines the airways (Jiang and Engelhardt, 1998). In people who suffer from CF, the decrease in Cl<sup>-</sup> secretion and alternately the hyperabsorption of Na<sup>+</sup>, leads to dehydrated mucus due to the lack of water following the transport of salt (see below and Figure 1). This accumulation of dehydrated and sticky mucus together with decreased PCL volume means that beating cilia are not as effective at removing mucus from the lungs, a breeding ground for pathogens is established and potentially lethal infections can develop (Gadsby *et al.*, 2006).

### 1.3 K<sup>+</sup> channels in epithelial cell physiology

The most studied airway epithelial ion channels are currently CFTR and ENaC. due to the fact that Cl<sup>-</sup> and Na<sup>+</sup> are the dominant transepithelial players in respiratory cell physiology, and the major candidates under investigation for CF therapies (Bardou et al, 2009). Potassium (K<sup>+</sup>) channels have been of less focus, even though about 40 types have been identified in airway and alveolar epithelial cells (Bardou et al; 2009). One of the most important roles that these channels play in epithelial cells is their ability to control membrane potential, and in turn, maintain the electrochemical gradient for the transport of ions and fluids (Salkoff et al., 2006). The presence of Na<sup>+</sup>/K<sup>+</sup>-ATPase pumps cause a greater intracellular  $K^+$  concentration ( $[K^+]_i$ ), leading to an overall efflux of  $K^+$  from the cell when selective K<sup>+</sup> channels are open, which in turn hyperpolarizes the cell membrane (Muth and Caplan, 2003). K<sup>+</sup> channels are also important for the absorptive properties of epithelial cells, and those lining the bronchi are involved in Na<sup>+</sup> absorption from the lumen into the cell (Muth and Caplan, 2003). As Na<sup>+</sup> is pumped out of the cell via Na<sup>+</sup>/K<sup>+</sup>-ATPase pumps on the basolateral membrane, K<sup>+</sup> is pumped into the cell. The intracellular K<sup>+</sup> then leaves the cell through apically and basolaterally located K<sup>+</sup> channels (Bernard et al., 2003; Moser et al., 2008). Na<sup>+</sup> is then able to move freely into the cell when Na<sup>+</sup> channels open on the apical membrane, due to the increased gradient for Na<sup>+</sup> that the Na<sup>+</sup>/K<sup>+</sup>-ATPase pump has created (Figure 1).

K<sup>+</sup> channels in epithelial cells are also responsible for creating the driving force for anion secretion through their ability to hyperpolarize the cell membrane (Smith and Frizzell, 1984; Cuthbert *et al.*, 2003). Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> co-transporters on the basolateral membrane transport Na<sup>+</sup>, K<sup>+</sup> and Cl<sup>-</sup> ions into the cell. Na<sup>+</sup> is removed via Na<sup>+</sup>/K<sup>+</sup>-ATPase pumps also located on the basolateral membrane, which add more intracellular K<sup>+</sup>. When K<sup>+</sup> channels on the apical and basolateral surface are activated, K<sup>+</sup> exits the cell, moving down its concentration gradient. This causes the cell to hyperpolarize, driving anions such as Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup> out through CFTR channels on the apical membrane (Figure 1) (Devor *et al.*, 1999). This close relationship between K<sup>+</sup>, Cl<sup>-</sup>, and Na<sup>+</sup> allows for the possibility of pharmacological treatments that target K<sup>+</sup> channels in diseases such as CF.

 $K^+$  channels are classified into 3 different groups according to the number of transmembrane domains (TMDs) the channel possesses (Bardou *et al.*, 2009). The first group encompasses  $K^+$  channels with 2 TMDs and includes the inward-rectifier  $K^+$  channels ( $K_{ir}$ ), such as  $K_{ir}6.1$ . The second group consists of  $K^+$  channels with 4 TMDs and contains the 2-pore  $K^+$  channels ( $K_2P$ ), which includes the members Twik -1, -2, Trek -1, -2, and Task -2, -3, -4. The final group, and of interest to this study, involves  $K^+$  channels with 6 TMDs, which consists of two subgroups, the voltage-dependent ( $K_v$ ) and calcium ( $K_v$ )-activated ( $K_v$ ) are channels. The  $K^+$  channel names and the genes they encode that are of interest to this project are described in Table 1.

### 1.4 Voltage-gated (K<sub>v</sub>) K<sup>+</sup> channels

One of the largest families of K<sup>+</sup> channels are the K<sub>v</sub> channels, which are known to include some of the most studied K<sup>+</sup> channels in the airway epithelium (Bardou *et al.*, 2009). These channels possess a tetramer of 6 TMDs and a single pore loop between S5 and S6 that contains the highly conserved glycine-tyrosine-glycine (GYG) amino acid signature that forms the K<sup>+</sup> selectivity filter, except for in K<sub>v</sub>11.1, which has a glycine-phenylalanine-glycine (GFG) signature (Heginbotham *et al.*, 1992; Pongs, 1992; Bardou *et al.*, 2009). They also have intracellular amino (NH<sub>2</sub>)- and carboxy (COOH)- terminals, and their S4 TMD is an important player in sensing voltage changes in the cell membrane (Figure 2A) (Benzanilla, 2000; Robbins, 2001). Although K<sub>v</sub>7.1 has gained much

attention as playing an important role in cardiac physiology since it is the main player in the disease Long QT1 syndrome (Sanguinetti and Jurkiewicz, 1990),  $K_v$ 7.5, members of the  $K_v$ 4 family,  $K_v$ 10.1, and  $K_v$ 11.1 have also surfaced as being interesting channels in epithelial cell physiology (as described below), and require further exploration.

#### 1.4.1 K<sub>v</sub>7.1 and 7.5

The K<sub>v</sub>7 family includes five members, K<sub>v</sub>7.1-7.5, which have been reported to associate with minK proteins, also known as KCNE subunits, and are specific beta (β) accessory subunits that can modify the channel's biophysical characteristics (Sanguinetti *et al.*, 1996; Robbins, 2001). For example, in the heart K<sub>v</sub>7.1 forms a complex with KCNE1 and generates the slow delayed rectifier K<sup>+</sup> current (I<sub>Ks</sub>) (Sanguinetti and Jurkiewicz, 1990). K<sub>v</sub>7.1 has been intensely studied in cardiac physiology, where it was first identified in a linkage study that was investigating cardiac arrhythmias, and mutations in this channel can lead to the heart arrhythmia Long QT1 syndrome (Sanguinetti and Jurkiewicz, 1990; Wang *et al.*, 1996). Multiple pharmacological inhibitors exist for these channels including linopirdine and its analogue XE991, which inhibit all five K<sub>v</sub>7 members, and chromanol 293B, which selectively inhibits K<sub>v</sub>7.1 (Warth *et al.*, 1996; Wang *et al.*, 1998; Zaczek *et al.*, 1998). It is more difficult to find suitable activators for these channels, however the Cl<sup>-</sup> channel blocker DIDS and mefenamic acid have been proposed as potential K<sub>v</sub>7 channel activators (Busch *et al.*, 1994; 1997).

K<sub>v</sub>7.1 expression has been detected in bronchial epithelial cells, where it is activated by intracellular cyclic adenosine monophosphate (cAMP) (Mall *et al.*, 2000). In Calu-3 cells, which are a widely used model of airway submucosal gland serous cells, it has been concluded that K<sub>v</sub>7.1 channels on the apical and basolateral membranes play an important role in the cell's basal and cAMP-activated anion secretion (Cowley and Linsdell, 2002; Moser *et al.*, 2008).

 $K_v7.5$ , another member of the  $K_v7$  channel family, has been less studied in airway epithelial cells. In the brain it plays a role in selectively transporting  $K^+$  ions and contributing to the muscarine sensitive (M-type)  $K^+$  current ( $I_m$ ) (Robbins, 2001). Although  $K_v7.2$  and  $K_v7.3$  have been suggested as the  $K_v7$  members responsible for the

slow activation and lack of inactivation characteristics of this current, K<sub>v</sub>7.4 and K<sub>v</sub>7.5 are also expressed in the brain and show similar M-current characteristics (Kubisch *et al.*, 1999; Lerche *et al.*, 2000). Because K<sub>v</sub>7.5 can co-assemble with K<sub>v</sub>7.3, it has been suggested that K<sub>v</sub>7.5 also contributes to the I<sub>m</sub> current (Lerche *et al.*, 2000). K<sub>v</sub>7.5 has also been reported to play a role in cell proliferation in skeletal muscle (Roura-Ferrer *et al.*, 2008), and along with K<sub>v</sub>7.3 it reportedly plays an important role in Na<sup>+</sup> transport in airway epithelial cells (Greenwood *et al.*, 2009).

#### 1.4.2 K<sub>v</sub>4.1, 4.2 and 4.3

Like the  $K_v$ 7 family of  $K^+$  channels, the majority of research on members of the  $K_v$ 4 family has been performed in the nervous and cardiovascular systems (Birnbaum *et al.*, 2004). They have the same topology as described for  $K_v$ 7 channels (Figure 2A). In mammals  $K_v$ 4 channels have three family members;  $K_v$ 4.1,  $K_v$ 4.2, and  $K_v$ 4.3 (Birnbaum *et al.*, 2004). These channels have been reported to interact with various auxiliary subunits and scaffolding proteins including KChIPs on the NH<sub>2</sub>-terminal end of the channel, and  $K_v$ 6 subunits on the COOH-terminal end (Barry *et al.*, 1998; Bahring *et al.*, 2001). In the nervous system it has been reported that these channels contribute to the transient outward A-type  $K^+$  current ( $I_A$ ), whereas in the cardiovascular system they contribute to the transient outward ( $I_{to}$ ) current (Birnbaum *et al.*, 2004). Inhibitors of these channels include heteropodatoxins and phrixotoxins (Sanguinetti *et al.*, 1997; Diochot *et al.*, 1999).

In the lungs all three members of the  $K_v4$  channel family express messenger ribonucleic acid (mRNA) in the alveolar epithelium, whereas only  $K_v4.2$  and 4.3 protein have been detected (Lee *et al.*, 2003).  $K_v4.2$  and 4.3 have also been reported as being apically expressed, and  $K_v\beta1.1$ , 2.1, and 3.1, as well as KChIP2 and 3 are also expressed in these tissues (Lee *et al.*, 2003). There is little known about the function of these channels in the respiratory epithelium; however, it has been suggested that they may be involved in  $K^+$  recycling (Lee *et al.*, 2003), oxygen sensing (O'Grady and Lee, 2003), and volume regulation (Harron *et al.*, 2009). Knowing their roles in bronchial epithelial cells may give insight towards their place in respiratory physiology.

#### 1.4.3 K<sub>v</sub>10.1 and 11.1

 $K_v 10.1$  is a member of the EAG family of  $K_v$  channels, which follows the typical K<sub>v</sub> channel topology (Figure 2A). There are three subfamilies within EAG; eag (ether-ago-go), elk (eag-like), and erg (eag-related), and the eag sub-family includes eag1, or K<sub>v</sub>10.1 (Bauer and Schwarz, 2000). These channels have been found to co-localize with the accessory subunits minK and miRP1 (McDonald et al., 1997; Abbott et al., 1999), and contribute to a slowly activating, non-inactivating outward current (Bauer et al., 2001). Inhibitors of this channel include the anti-histamine astemizole and the antidepressant imipramine (Garcia-Ferreiro et al., 2004). K<sub>v</sub>10.1 has been reported to play a role in myoblast differentiation and the cell cycle (Occhiodoro et al., 1998), while dysfunctional K<sub>v</sub>10.1 can cause increased neural excitability (Ganetzky and Wu, 1983). This channel has received attention as potentially playing an important role in cancer because it is aberrantly expressed in many cancerous tissues including the skin, breast, and colon (Meyer et al., 1999; Pardo et al., 1999; Ousingsawat et al., 2007). In MCF-7 cells, a widely used cell line of cancerous mammary epithelial cells, K<sub>v</sub>10.1 plays a role in the progression of the cell through the  $G_1$  phase of the cell cycle and cell proliferation (Ouadid-Ahidouch et al., 2001; Roy et al., 2008).

K<sub>v</sub>11.1 is a member of the erg sub-family of EAG K<sub>v</sub> channels, and is most noted as contributing to the rapid component of the cardiac delayed rectifier K<sup>+</sup> current (I<sub>Kr</sub>), as well as playing a major role in the repolarization phase of the cardiac action potential (Sanguinetti *et al.*, 1995). Inhibitors of this channel include the anti-arrhythmic drug E-4031 (Yao *et al.*, 2005) and the scorpion toxin Ergtoxin (Scaloni *et al.*, 2000). The effects that this channel has in cardiovascular physiology have led to the discovery that a loss-of-function mutation in K<sub>v</sub>11.1 causes Long QT syndrome 2 (Curran *et al.*, 1995). K<sub>v</sub>11.1 has been reported to play a role in pacemaker activity in interstitial cells of Cajal (Zhu *et al.*, 2003), along with insulin secretion from pancreatic β-cells (Rosati *et al.*, 2000). It has also been detected as being aberrantly expressed in multiple primary carcinomas but not in their normal counterparts (Bianchi *et al.*, 1998; Cherubini *et al.*, 2000; Smith *et al.*, 2002; Wang *et al.*, 2002a). In MCF-7 cells, K<sub>v</sub>11.1 channels play a role in cell volume regulation (Roy *et al.*, 2008), making them interesting players in epithelial physiology.

# 1.5 Calcium-activated (K<sub>Ca</sub>) K<sup>+</sup> channels

 $K_{Ca}$  channels are expressed in many excitable and non-excitable tissues, and are gated by either both membrane potential and intracellular  $Ca^{2+}$  concentrations ( $[Ca^{2+}]_i$ ), or solely  $[Ca^{2+}]_i$  (Vergara *et al.*, 1998). The  $K_{Ca}$  channel family contains two subfamilies: Slo and SK channels, which differ in their conductance and gating properties.  $K_{Ca}1.1$  is a member of the Slo subfamily (Slo1), and has a large unitary conductance. It is also gated by both  $[Ca^{2+}]_i$  and membrane depolarization (Sah, 1996). On the other hand,  $K_{Ca}3.1$  is a member of the SK subfamily (SK4), has a smaller unitary conductance and is gated by  $[Ca^{2+}]_i$  only (Sah, 1996).

#### 1.5.1 K<sub>Ca</sub>1.1

The  $K_{Ca}1.1$  channel has similar topology to  $K_v$  channels; however it also differs in various ways. It is a tetrameric structure but it contains an additional TMD (S0) (Berkefeld et al., 2010). This causes the NH<sub>2</sub>-terminal end to relocate to the extracellular side of the channel while the COOH-terminal end remains on the intracellular side (Figure 2B). This COOH-terminal end is much larger than that seen in typical 6TMD K<sup>+</sup> channels and is the location of the Ca<sup>2+</sup> binding site that allows for channel activation (Meera et al., 1997; Magleby, 2003). Since K<sub>Ca</sub>1.1 is also activated by membrane depolarization, its voltage sensor is still under investigation, however it has been suggested that the TMDs S2-S4 play a role in this biophysical mechanism (Pantazis et al., 2010). Most  $K_{Ca}1.1$  channels are associated with the  $\beta$ -subunits BK $\beta$ , which play a role in mediating the channel's signaling (Berkefeld et al., 2006). This channel is activated by benzimidazolones, including NS004 and NS1619, and inhibited by the scorpion toxins iberiotoxin and charybdotoxin, as well as the mycotoxin, paxilline (McKay, 1994; Holland et al., 1996; Strobaek et al., 1996; Kraft et al., 2003; Wei et al., 2005). Physiologically these channels have been suggested to play a role in many areas, including neuronal after-hyperpolarization (Faber and Sah, 2003), oxygen sensing in the carotid bodies (Williams et al., 2004), as well as K<sup>+</sup> secretion in the kidneys (Pluznick and Sansom, 2006). They have also been reported as being involved in cell proliferation in breast cancer (Ouadid-Ahidouch et al., 2004), and regulating cell volume in the presence of hyposmotic shock in bronchial epithelial cells (Fernandez-Fernandez et al.,

2002). This makes  $K_{Ca}1.1$  an interesting player in many of the physiological processes that human bronchial epithelial cells participate in.

#### 1.5.2 K<sub>Ca</sub>3.1

The SK subfamily of  $K_{Ca}$  channels has four members (SK1-4) and of those members, SK4 or K<sub>Ca</sub>3.1 is the only one that is restricted to nonneuronal tissues (Stocker, 2004). In contrast to  $K_{Ca}1.1$  channels, there is no dependence on membrane potential in the biophysical characteristics of K<sub>Ca</sub>3.1 and therefore its S2-S4 segments do not contribute to voltage sensing. Its gating kinetics depend entirely on changes in [Ca<sup>2+</sup>]<sub>i</sub>, and its channel topology is much more similar to  $K_v$  channels than  $K_{Ca}1.1$  (Figure 2A) (Kohler et al., 1996; Berkefeld et al., 2006). It was originally hypothesized that there was a binding site for Ca<sup>2+</sup> within the K<sub>Ca</sub>3.1 channel; however, further investigation revealed that exogenous calmodulin (CaM) was instead the Ca<sup>2+</sup> sensor related to this channel (Xia et al., 1998). Activators of K<sub>Ca</sub>3.1 include 1-ethyl-2-benzimidazolinone (EBIO), while clotrimazole and TRAM-34 inhibit the channel (Devor et al., 1996; Ishii et al., 1997; Jensen et al., 1999). K<sub>Ca</sub>3.1 plays an important role in regulating cell proliferation in T lymphocytes, since it controls the progression of these cells through the late  $G_1$ phase of the cell cycle (Ghanshani et al., 2000). K<sub>Ca</sub>3.1 also plays various roles in epithelial physiology, from Ca<sup>2+</sup>-dependent ion transport in the airways (Devor et al., 1999; Cowley and Linsdell, 2002), to regulating cell volume in times of hyposmotic stress in tracheal epithelial cells (Vasquez et al., 2001). Despite the fact that K<sub>Ca</sub>3.1 channels are becoming very widely studied, their roles in airways epithelial cells are still not completely clear.

#### 1.6 K<sup>+</sup> channels in cell proliferation

As mentioned above, the epithelium also plays an important role in wound repair and cell proliferation in the airways. The respiratory system is always exposed to the external environment; therefore, there is an increased risk for epithelial injury if the MCC defense mechanism does not work properly. Respiratory diseases such as CF are especially prone to tissue damage due to increasing inflammation and epithelial wound repair must be implicated in order to keep the lungs healthy (Bardou *et al.*, 2009).

Epithelial repair begins after the cell is exposed to injury by infection or inflammation. Neighbouring epithelial cells spread and de-differentiate and then migrate to cover the injured areas. Airway epithelial progenitor cells also migrate and proliferate in order to increase cell number. These cells then re-differentiate in order to function as airway epithelial cells (Bardou *et al.*, 2009; Crosby and Waters, 2010). It has also been shown that after epithelial cells are injured those that survive release growth factors such as epidermal growth factor (EGF), which acts through EGF receptors (EGF-R), and mediate a mitogenic response important to migration and airway epithelial repair (Boxall *et al.*, 2006; Trinh *et al.*, 2007).

Not only is EGF an important component to the airway repair processes, but it has also been shown that  $K^+$  channels are also important in alveolar and bronchial repair (Trinh *et al.*, 2007; Trinh *et al.*, 2008). In these studies it was found that when  $K_v$ 7.1 and  $K_{Ca}$ 3.1 were inhibited in bronchial epithelial cells, EGF-stimulated wound healing, cell migration and cell proliferation was reduced. It was also shown that CF bronchial epithelial cells took longer to heal in the presence of EGF than normal bronchial epithelial cells and this may be related to the expression of  $K^+$  channels.  $K_v$ 7.5 has also been reported to play a role in the proliferation of skeletal myoblast cells in rats, as it is up-regulated in myoblast growth and inhibition causes the arrest of myoblasts in the  $G_1$  phase of the cell-cycle (Roura-Ferrer *et al.*, 2008).

The relationship between K<sup>+</sup> channel activity and cell proliferation is still not completely understood, as it stems from previous studies looking at the aberrant or over-expression of K<sup>+</sup> channels in cancer and the dependence of cell-cycle progression to K<sup>+</sup> channels (Figure 3) (Wonderlin and Strobl, 1996; Bianchi *et al.*, 1998; Meyer *et al.*, 1999; Cherubini *et al.*, 2000; Ouadid-Ahidouch *et al.*, 2001; Smith *et al.*, 2002; Wang *et al.*, 2002). It has been concluded that in order to progress through the G<sub>1</sub> phase of the cell cycle, K<sup>+</sup> channels are required to hyperpolarize the membrane. Thus when K<sub>v</sub>10.1 was inhibited in MCF-7 cells, it decreased proliferation and arrested the cell in G<sub>1</sub> (Wonderlin and Strobl, 1996; Ouadid-Ahidouch *et al.*, 2001). It has also been shown that by silencing K<sub>v</sub>4.1 channels through small interfering RNA (siRNA) targeting, proliferation in tumourigenic human mammary epithelial cells was significantly reduced (Jang *et al.*, 2009). Since these channels are important in cancer epithelial cell pathophysiology and in

other normal cell types, perhaps there is a place for them in cell proliferation relating to normal and CF bronchial epithelial cell physiology, and further investigation is required to examine this theory.

#### 1.7 K<sup>+</sup> channels in cell volume regulation

Epithelial cells are also involved in the regulation of cell volume, and changes in cell volume have been one of the main candidates as to how K<sup>+</sup> channel activity is related to cell proliferation, since cells change their volume as they progress through the cell cycle (Lang et al., 1998). Cells are also constantly exposed to altered intracellular and extracellular osmolarities, and they are able to maintain an optimum volume by activating various membrane proteins (Lang et al., 1998). Water movement parallels these changes in osmolarity, and contributes to the changes that occur in cell volume. In response to hyperosmotic stress, water will exit the cell via osmosis and through water-transporting proteins on the cell membrane, including aquaporins and the K<sup>+</sup>/Cl<sup>-</sup>-co-transporter (KCC), due to the osmotic pressure gradient, (Zeuthen, 1994; Agre, 2006). Cells will then shrink in order to equilibrate the intracellular and extracellular osmolarities, and then attempt to return to their normal volume by activating Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> co-transporters, as well as Na<sup>+</sup>/H<sup>+</sup> exchangers and in some cells, Na<sup>+</sup> channels. This is then followed by a gain of water and known as regulatory volume increase (RVI) (Lang et al., 1998; Mongin and Orlov, 2001). In contrast, when cells are exposed to hyposmotic stress, water will enter the cell and cause it to swell, activating K<sup>+</sup> and anion channels. This is then followed by the loss of water, which allows the cell to decrease back down in volume, known as regulatory volume decrease (RVD) (Lang et al., 1998). Hyposmotic changes to the external environment have been previously shown to affect human airway epithelial cells, and these cells responded by activating  $K_{Ca}$  channels, although different members of the K<sub>v</sub> family also reportedly play a role in the RVD response (Vazquez *et al.*, 2001; Fernandez-Fernandez et al., 2002; Harron et al., 2009). It has also been shown that K<sub>v</sub>7.1 and K<sub>v</sub>11.1 play an important role in regulating the RVD response in MCF-7 cells (vanTol et al., 2007; Roy et al., 2008). However, in Calu-3 cells it was shown that members of the  $K_v$ 7 family other than  $K_v$ 7.1, as well as  $K_v$ 4.1 and  $K_v$ 4.3 all contributed to

the RVD response (Harron *et al.*, 2009). It is important to investigate which K<sup>+</sup> channels may play integral roles in mediating the RVD response in bronchial epithelial cells.

#### 1.8 16HBE14o- and CFBE41o- cells as model cell lines

For this research project, both normal human bronchial epithelial cells, as well as those with a CF phenotype were used. The 16HBE14o- (HBE) cell line is a widely used model that was generated by Cozens and colleagues in 1994 by the transformation of normal human bronchial epithelial cells. These cells are widely used due to their easy maintenance and their avoidance of many problems that occur when using primary tissues, such as the high costs and reproducibility issues (Ehrhardt *et al.*, 2002). HBE cells maintain the differentiation associated with native human bronchial epithelial cells, including the ability to become polarized and the presence of functional CFTR protein (Ehrhardt *et al.*, 2002).


The CFBE41o- (CFBE) cell line is another widely used model that was generated by the transformation of CF bronchial epithelial cells. Not only are these cells homozygous for the ΔF508 mutation, but the mutation also stays intact over multiple passages (Ehrhardt *et al.*, 2005). CFBE cells can also maintain the differention associated with human CF bronchial epithelial cell including the formation of cell layers that are not only electrically tight but also have cell-cell connections that are still functional (Ehrhardt *et al.*, 2005). Although there are limitations with using cell lines over native cells (see Section 4.4.4), because HBE and CFBE cells maintain many of the same characteristics as their native cell counterparts, including the expression of particular K<sup>+</sup> channels (Namkung *et al.*, 2009), they are good models for studying the different physiological functions of healthy and CF human bronchial epithelial cells.

#### 1.9 Study Objectives

The basis of this project is to investigate the physiological role that various  $K_v$  and  $K_{Ca}$  channels play in human bronchial epithelial cells. Since these channels have been shown to play important roles in cell proliferation and cell volume regulation in other cell lines, it is of interest to delineate their functions in bronchial epithelial cells that are both healthy, as well as those representing the CF phenotype. Based on the evidence, I

hypothesize that  $K_v7.1$ , 7.5, 4.1, 4.2, 4.3, 10.1 and 11.1, and  $K_{Ca}1.1$  and 3.1 play an important role in cell proliferation and regulation of cell volume under hyposmotic stress and that these findings could give some insight towards finding a cure for the devastating disease that is CF.

# A HEALTHY INDIVIDUALS



# **B CF INDIVIDUALS**







Figure 1. Representative model of ion transport in airway epithelial cells. In order to maintain an adequate PCL volume there must be a balance between Na<sup>+</sup> absorption and Cl secretion across the epithelial cells that line the airways. (A) The Na<sup>+</sup>/K<sup>+</sup>-ATPase on the basolateral membrane sets up the electrochemical gradient of the cell. As it actively pumps 3 Na<sup>+</sup> ions out of the cell, it pumps 2 K<sup>+</sup> ions in. These K<sup>+</sup> ions are recycled through basolateral and potentially apical  $K^+$  channels. The decrease in  $[Na^+]_i$  inside the cell creates the driving force for the entry of Na<sup>+</sup> through apically located ENaC. This Na<sup>+</sup> is then expelled via the Na<sup>+</sup>/K<sup>+</sup>-ATPase pump. As Na<sup>+</sup> ions undergo transepithelial transport, water and other ions osmotically follow this movement via the paracellular pathway. The Na<sup>+</sup>/2Cl<sup>-</sup>/K<sup>+</sup> co-transporter on the basolateral membrane then transports Na<sup>+</sup>, 2Cl<sup>-</sup> and K<sup>+</sup> ions into the cell, and Na<sup>+</sup> exits via the Na<sup>+</sup>/K<sup>+</sup>-ATPase pump as K<sup>+</sup> is again recycled by K<sup>+</sup> channels on the basolateral and apical membranes. Cl<sup>-</sup> undergoes transepithelial transport and is secreted from apical Cl<sup>-</sup> channels, including CFTR. Once again, water and other ions osmotically follow this Cl movement via the paracellular pathway. (B) In people who suffer from CF, the dysfunction in their CFTR protein causes a decrease in Cl<sup>-</sup> and other anion secretion. This decreases the paracellular transport of water to the lumen and creates dehydrated mucus that causes an array of complications in the airways (Bardou et al., 2008).



B



**Figure 2. Structural model of various types of K**<sup>+</sup> **channels.** (A) Represents  $K_v$  channel topology, with 6 TMDs (S1-S6), the pore loop between S5 and S6 (P) and the intracellular NH<sub>2</sub> and COOH termini, shown by the N- and C- terminus respectively. (B) Represents the  $K_{Ca}1.1$  channel topology, with 7 TMDs (S0-S6), the pore loop between S5 and S6 (P) and the extracellular NH<sub>2</sub> terminus and longer intracellular COOH terminus (N- and C- terminus respectively) (Bardou *et al.*, 2008; Berkefeld *et al.*, 2010).



**Figure 3. Schematic representation of the cell cycle.**  $G_1$ , S,  $G_2$  and M represent the first gap, DNA synthesis, second gap and mitotic phases of the cell cycle respectively. The cell grows in the  $G_1$  and when it becomes large enough it enters the S phase. The S phase consists of DNA synthesis and chromosomes duplicate. During the  $G_2$  phase, the cell continues to grow and prepares for cell division, which occurs during the M phase and creates two daughter cells.  $K^+$  channels play a role in the cell's progression through various phases of the cell cycle, along with various cyclins and cyclin-dependent kinases (CDK) (Hartwell *et al.*, 2001).

#### **CHAPTER 2: MATERIALS AND METHODS**

#### 2.1 Cell Culture

cystic fibrosis human bronchial epithelial cells and CFBE41o- (CFBE) cystic fibrosis human bronchial epithelial cells were obtained from Dr. Dieter Gruenert (California Pacific Medical Center, San Francisco, CA, USA), and were originally immortalized through transformation with the plasmid pSVori (Cozens *et al.*, 1992; Cozens *et al.*, 1994). Both cell lines were maintained in a humidified incubator at 37°C with 5% CO<sub>2</sub>. Stock cells, which were passaged each week, and grown in Minimum Essential Media (MEM) containing phenol red, supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 U/ml streptomycin (all from Invitrogen, Burlington, ON). Medium was replaced every 2-3 days from stock cells that were grown in 75 cm² polystyrene tissue culture flasks (Corning, Lowell, MA, USA) and coated with 1.5 ml of a fibronectin coating solution (1-5 μg/cm²) for 3 hr before use (Invitrogen; Sigma-Aldrich, Oakville, ON; BD Biosciences, Franklin Lakes, New Jersey, USA) (Appendix C), as described in Ehrhardt *et al.*, 2002. All experiments were performed between passages 8-20 and occurred when the cells reached between 90-100% confluency.

To passage the cells, the media was removed and they were washed with 10 ml of RNase-free 1X phosphate buffered saline (PBS) with 1.1 mM glucose and 684  $\mu$ M EDTA (1XPBS GE) (Appendix C). Cells were detached from the surface of the flask using 1 ml of 0.25% trypsin (Invitrogen) and incubated at 37°C for 20-30 min. After the cells were completely detached they were re-suspended in 6 ml of media, counted using a Coulter Counter (see below) and from this solution 4,000,000 HBE and 500,000 CFBE cells were put into the stock flasks in order to continue the cell line. HBE cells were smaller than CFBE cells and therefore more cells were required for the stock flasks to become confluent (HBE= 15.74  $\pm$  0.054  $\mu$ m; CFBE= 18.64  $\pm$  0.19  $\mu$ m; n=17). For each individual experiment the number of cells, how they were cultured and their treatment protocol is described below.

#### 2.2 Cell Counting

Using a Coulter Counter, cell number was measured as a means to assess cell proliferation during the cell cycle on HBE and CFBE cells as follows. Approximately 200,000 HBE and 64,000 CFBE cells were put into each well of a six-well polystyrene tissue culture plate (BD Biosciences) coated with fibronectin (see above). The cells were incubated at 37°C in 10% FBS MEM for 24 hr, allowing them to attach to the plates. Cells were then treated in 1% FBS MEM with specific drugs at differing concentrations and durations, as described in Table 2. After 48 hr in the presence of a drug or vehicle control, the media was removed and each well was washed with 1XPBS GE. 1 ml of 0.25% trypsin was added to each well and the plates were incubated at 37°C for 10 min, or until the cells were completely detached. A Coulter Counter (Beckman Coulter Canada, Inc., Mississauga, ON) was used to count the number of cells suspended in each sample. 1 ml of each sample was added to 9 ml of 1XPBS GE, mixed by pipetting, and placed into the Coulter Counter. Briefly, as cells flow into the aperture, they increase the resistance between the electrodes, and therefore increase the voltage as well. Each cell that passes through the aperture records a voltage pulse, and the number of pulses measured equals the number of cells in a sample, whereas the amplitude of the pulse is proportional to the cell volume (Beckman Coulter, Inc., 2011).

#### 2.3 Lactate Dehydrogenase (LDH) Cytotoxicity Assay

In order to measure the potential cell death in response to drugs, LDH cytotoxicity assays (Caymen Chemical, Michigan, USA) were performed. LDH is a soluble enzyme located in the cytosol of cells, and released into the surrounding culture medium upon cell damage or lysis, and is commonly used as an indicator of cell cytotoxicity (Haslam *et al.*, 2000; Wolterbeek and van der Meer, 2005). Either 50,000 HBE or 20,000 CFBE cells were plated in 24-well polystyrene tissue culture plates coated with fibronectin (BD Biosciences) and grown for 24 hr. The next day they were treated with specific drugs at differing concentrations (Table 2) and returned to the incubator for 48 hr. 500 μl of medium from each well was transferred to 1.5 ml sterile microcentrifuge tubes, centrifuged at 400 X g relative centrifugal force (RCF) for 5 min. 100 μl of each supernatant was transferred to corresponding wells in a 96-well polystyrene tissue culture

plate (BD Biosciences). 100  $\mu$ l of the reaction solution was added to each well, which consisted of 100X of each NAD<sup>+</sup>, lactic acid, 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl tetrazolium (INT), LDH diaphorase and finally enough assay buffer to bring the reaction solution up to the amount needed to add 100  $\mu$ l to each well (eg. 17 wells = 1700  $\mu$ l reaction solution). The 96-well plate was incubated for 30 min at room temperature with gentle shaking and then the absorbance was read at 490 nm on a microplate reader (Beckman Coulter Canada, Inc.).

#### 2.4 RNA Extraction

In order to detect specific K<sup>+</sup> channel mRNA expression in HBE and CFBE cells, total RNA was extracted and reverse transcription-polymerase chain reaction (RT-PCR) was performed. As a first step either 200,000 HBE or 64,000 CFBE cells were cultured in 6-well plates coated with fibronectin and grown to approximately 90-100% confluency in order to optimize the amount of RNA extracted. After removing the media each well was washed with 2 ml of 1XPBS GE for 30 s and 1 ml of Trizol Reagent<sup>TM</sup> (Invitrogen) was added to each well. Cells were then incubated at room temperature for 5 min and then homogenized by pipetting. Each sample was transferred to a 1.5 ml sterile microcentrifuge tube and 200 µl of chloroform (Fisher Scientific, Ottawa, ON) was added. The micro-centrifuge tubes were vortexed for 15 s, incubated at room temperature for 3 min and centrifuged at 4°C for 15 min at 13,000 revolutions per minute (RPM). 400 µl of the top colourless aqueous phase containing RNA was removed and transferred into new 1.5 ml sterile micro-centrifuge tubes and 500 µl of isopropanol (Sigma-Aldrich) was added. The tubes were then vortexed, incubated at room temperature for 10 min and centrifuged at 4°C for 10 min at 13,000 rpm. The supernatant was removed and the tubes were centrifuged at room temperature to bring down any residual RNA. This RNA pellet was then washed with cold 75% ethanol. The tubes were vortexed and then centrifuged at 4°C for 5 min at 13,000 rpm and the wash step was repeated. Finally, the supernatant was removed, and with the lids of the tubes left open they were placed in the water bath at 55-60°C to allow the ethanol to evaporate. After this, 20 µl of autoclaved water was added to each tube and they were stored at -80°C.

The concentration and purity of the extracted RNA was measured using a GeneQuant Pro Spectrophotometer (Biochrom, Cambridge, U.K.). 1  $\mu$ l of each sample was added to 69  $\mu$ l of sterile water in 0.5 ml micro-centrifuge tubes and vortexed. The RNA sample was then added to a cuvette and inserted into the spectrophotometer, and the RNA concentration (in  $\mu$ g/ $\mu$ l) was recorded. The purity of the RNA was measured and recorded as the 260/280 ratio and a value of > 1.8 indicated a sample of nucleic acid with minimal protein contamination.

#### 2.5 Reverse Transcription of RNA to Single Stranded cDNA

Complimentary deoxyribonucleic acid (cDNA) was formed by RT of the RNA samples. 2 μg of RNA was added to 1 μl of 500 μg/ml oligoDT (Promega, Madison, WI) and sterile water was added to reach a final volume of 15 μl. Samples were heated to 70°C for 3 min and then cooled to 4°C for 2 min. 2 μl of 1<sup>st</sup> strand cDNA buffer, 2 μl of 5mM deoxyribonucleoside triphosphate (dNTP) and 1 μl of 200 U/μl Moloney Murine Leukemia Virus (M-MLV) RT (all Invitrogen) were added to each sample and mixed by pipetting. A negative reverse transcription was performed as a control step, which consisted of 1 μl of sterile water instead of the M-MLV RT. The samples were incubated at 42°C for 1 hr and then heated to 80°C for 5 min in order to inactivate the reverse transcription enzyme. 80 μl of sterile water was added to each sample once the reaction was complete to bring the final volume up to 100 μl and the samples were stored at -20°C.

#### 2.6 Polymerase Chain Reaction (PCR)

The specific gene fragments for the K $^+$  channels of interest were amplified using PCR. For each reaction, each sample contained 2  $\mu$ l of cDNA, 15.5  $\mu$ l sterile water, 1.5  $\mu$ l of 25mM MgCl $_2$  (Fermentas, Burlington, ON), 2.5  $\mu$ l of 10X Taq Buffer (Fermentas), 1  $\mu$ l of 5mM dNTP, 1  $\mu$ l of sense primer and 1  $\mu$ l of antisense primer (Invitrogen) and 0.5  $\mu$ l of Taq DNA Polymerase (Fermentas). Primer information, annealing temperatures and references are described in detail in Table 3. The conditions were optimized for each cell line and the working concentrations of each primer was 10  $\mu$ M. Sterile water was substituted for cDNA in the negative control experiments and the housekeeping gene

HPRT was used in positive control experiments to test the integrity of the cDNA. cDNA from another airway epithelial cell line, Calu-3 was used as a positive control for certain genes.

#### 2.7 Agarose Gel Electrophoresis

PCR products were viewed by agarose gel electrophoresis. A 1.5% agarose gel was made by adding 50 ml of 1XTris/Borate/EDTA (TBE) buffer (Appendix C) to 0.75 g of agarose (Fisher Scientific) and microwaving for 2 min. 2.5 μl of 0.5 μg/μl ethidium bromide (Sigma-Aldrich) was added to the mixture, which was then poured into the gel box and allowed to set for 20 min. 5 μl of a 100 bp DNA Ladder (Fermentas) was added to the first lane in the gel and then 15 μl of each PCR reaction, which had been mixed with 5 μl of 6X loading dye (Fermentas), was added to the next lanes. The voltage was set to 90 volts (V) and the gel was run for 45 min. A UV Transiluminator UVP BioDoc-It system (Upland, CA, USA) was used to view the amplicons.

#### 2.8 Western Blotting

Western blotting was performed to detect protein expression in both cell lines. Both HBE and CFBE cells were grown in 100 X 20 mm polystyrene tissue culture dishes (BD Biosciences) to 90-100% confluency in order to optimize the amount of protein extracted, and total cellular protein was extracted. Cells were rinsed twice with 10 ml of cold 1XPBS GE and then 500 μl of RIPA buffer (Appendix C), with 5 μl HALT<sup>TM</sup> protease-inhibitor cocktail (Fisher Scientific) and 2 mM phenylmethanesulfonyl fluoride (PMSF) (Sigma-Aldrich) was added to the cells and they were left on ice for 30 min. The cells were then detached from the dishes using cell scrapers (Sarstedt Inc, Newton, NC, USA) and placed in a 1.5 ml micro-centrifuge tube and centrifuged at 13,000 RPM for 30 min at 4°C. The supernatant was then analyzed using the Bradford method (Bio-Rad, Hercules, CA, USA) and a microplate reader to measure the protein concentration in each sample prior to storage at -20°C. 10-60 μg of HBE or CFBE protein was used per lane for Western blot analysis and diluted with 2X Laemelli loading buffer (Bio-Rad) with 5% (<sup>V</sup>/<sub>V</sub>) β-mercaptoethanol and heated in a water bath for 3 min at 95°C. Sodium dodecyl sulphate (SDS) polyacrylamide electrophoresis gels were used to separate the proteins

and run for 1.5 hr in 1X running buffer (Appendix C). These gels were composed of a stacking gel (5%) and a resolving gel (7.5%) (Appendix C). First, the protein migrated down the stacking gel at 70 V and the voltage was then increased to 100 V when the protein reached the resolving gel. Once the protein had migrated down the resolving gel, the stacking gel was removed and the protein was transferred onto a nitro-cellulose membrane at 100 V for 1 hr in transfer buffer on ice (Appendix C). Membranes were then blocked for 1 hr in room temperature with 5% skim milk powder in Tris-base saline (TBS) containing 0.1% Tween 20 (Bio-Rad) (TBS-T) (Appendix C). The membranes were incubated overnight at 4°C with gentle shaking, with specific primary antibodies in milk (Sigma-Aldrich). After primary antibody incubation, membranes were washed 3 times for 15 min with TBS-T and once for 15 min with TBS. Membranes were then incubated for 2 hr at room temperature and shaken gently with the appropriate secondary antibody in milk. The specific primary and secondary antibody information is described in Table 4. After secondary antibody incubation each membrane was once again washed 3 times for 15 min in TBS-T and once for 15 min in TBS. In order to visualize protein band expression on the nitro-cellulose membrane, the Amersham Enhanced Chemiluminesence Plus Western blotting detection system (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) was used following the manufacturers' protocol.

#### 2.9 Cell Volume Regulation

Experiments were performed to measure changes in cell volume under conditions of altered osmolarities following protocols designed by vanTol and colleagues in 2007, and Harron and colleagues in 2009. Briefly, single HBE or CFBE cells were plated on glass coverslips in 35 X 10 mm polystyrene tissue culture dishes (BD Biosciences) and incubated between 3 to 7 hr to allow the cells to attach to coverslips. Bath solutions are described in Appendix 1. The osmolarities of the bath solutions were measured using a vapour pressure osmometer (Wescor, Logan, UT, USA) and the respective osmolarities were  $124.2 \pm 0.49$  mOsM,  $180.3 \pm 0.46$  mOsM,  $206.6 \pm 0.52$  mOsM,  $259.5 \pm 0.70$  mOsM,  $327.3 \pm 0.46$  mOsM,  $482.3 \pm 0.41$  mOsM and  $528.5 \pm 0.43$  mOsM (n=24). The glass coverslips were first placed on the microscope, and solutions were continuously perfused at a rate of 1 ml/min using a peristaltic pump (Gilson, Middleton, WI, USA).

Cells were equilibrated in isosmotic (327 mOsM) solution for 5 min and then switched to a hyperosmotic or hyposmotic solution containing either vehicle or drug for 25 min. At the end of the experiment, cells were returned to isosmotic conditions for 5 min in order to ensure their viability and ability to return to their original size. For experiments involving K<sup>+</sup> channel inhibitors and RVD, the hyposmotic solution measuring 180 mOsM was used, since it had the greatest effect on the RVD response (Figure 8). Cells were visualized using a Zeiss Axioskop FS microscope (Oberkochen, Germany) and a waterimmersion 63X objective lens. Every minute, images of the cells were captured by a PixelLINK 1394 camera with accompanying Capture SE version 4.1 software (PixelLINK, Ottawa, Canada) and cell area was analyzed with ImageJ version 1.36b software (National Institute of Health, Bethesda, MD, USA). Assuming a spherical shape, cellular radius (R) and volume (V) were calculated from the equations  $R = \sqrt{(area/\pi)}$  and  $V = 4/3(r\pi^3)$ , respectively, and cell volume was normalized to that at t = 0 (vanTol et al., 2007). Results for RVD experiments were presented as percentage of RVD (% RVD) ± standard error (SE). % RVD was calculated as 100(1-[(V<sub>25min</sub>-1)/(V<sub>max</sub>-1)]), where V<sub>max</sub> is the peak volume in the hyposmotic solution. % RVI was calculated as 100(1-[(V<sub>25min</sub>- $1/(V_{min}-1)$ ]), where  $V_{min}$  is the minimum volume in hyperosmotic solution (Harron et al., 2009).

#### 2.10 siRNA Transfection

HBE cells were transfected with  $K_v7.1$  and  $K_v7.5$  siRNA duplexes using siTran 1.0 Transfection Reagent, tagged with Trilencer-27 TYE-563 labeled fluorescent transfection control siRNA duplex (1 nmol) (all from OriGene Technologies, Rockville, MD, USA). Three different gene specific 27mer siRNA duplexes (2 nmol per vial) for each  $K^+$  channel were provided, as well as a universal scrambled negative control siRNA duplex (2 nmol) and an RNAse free siRNA duplex re-suspension buffer. Each siRNA duplex was re-suspended in 100  $\mu$ l RNAse free duplex buffer to produce a 20  $\mu$ M final concentration, while the fluorescent transfection control siRNA duplex was re-suspended in 100  $\mu$ l RNAse free duplex buffer to produce a 10  $\mu$ M final concentration. Duplexes were then heated to 94°C for 2 min, cooled at room temperature and stored at -20°C until used. Experiments were performed on cells in 6-well plates when they reached 60%

confluency. Briefly, 5 µl of siRNA was mixed with 140 Opti-MEM® Reduced Serum Media (opti-MEM) (Invitrogen) and incubated at room temperature for 5 min. In parallel, 20 µl siTrans reagent and 115 µl opti-MEM medium were combined and incubated for 5 min. The siRNA/Opti-MEM mixture was then added to the siTrans/Opti-MEM mixture and incubated for 10 min. While incubating, cells were washed with 1 ml 1XPBS GE for 30 s. At the end of the incubation period, the siRNA/siTrans mixture was pipetted onto the cells and 2.5 ml of MEM (without FBS) media was placed on top. Next the cells incubated for 24 hr and were then switched to 5% FBS MEM medium. Protein extraction was performed 48 hr after the transfection and analyzed by Western blot.

#### 2.11 Plasmid DNA Transfection

In order to suppress the expression of K<sub>v</sub>7.1 in HBE cells, site-directed mutagenesis that had been previously performed in our lab was used to create a NH<sub>2</sub>terminal truncated isoform of K<sub>v</sub>7.1 that acts as a dominant negative mutation known as  $\Delta N$ -  $K_v 7.1$  (Jiang et al., 1997; van Tol et al., 2007). Bacterial stocks for this mutation were grown up and DNA was extracted following the QIAprep Spin Midiprep Kit protocol (QIAGEN Inc., Toronto, ON). The concentration of the extracted DNA was measured (in ng/µl) using a GeneQuant Pro Spectrophotometer (see 2.4 RNA Extraction). HBE cells were plated in 60 X 15 mm polystyrene tissue culture dishes (BD Biosciences) and grown in 10% FBS MEM (without antibiotic) media until they reached 60% confluency. These cells were then transfected with pIRES2-EGFP- $\Delta$ N- K<sub>v</sub>7.1 plasmid DNA. Briefly, 3.33 µl of DNA (600 ng/ul) was added to 100 µl of opti-MEM media in one tube, while 6 μl lipofectamine 2000 (Invitrogen) was added to 100 μl of opti-MEM media in another tube. Both mixtures were left to incubate at room temperature for 5 min, and then added together and left to incubate for 20 min. This mixture was then added to the cells after the existing media was removed, followed by 1.5 ml of serum-free and antibiotic-free MEM media. The cells were incubated at 37°C for 5 hr and then switched to 10% FBS MEM media and allowed to grow in the incubator. 48 hr after transfection, the cells were washed with 1 ml PBS GE and 200 µl trypsin was added to each plate for 10 min at 37°C in order to detach them. The cells were resuspended in 1 ml of 10% FBS MEM media and seeded on glass coverslips in 35

X 10 mm polystyrene tissue culture dishes and incubated for 3 to 7 hr before use in order for cells to attach to the coverslips. Cell volume experiments were then performed (see Section 2.9). Control experiments were performed by transfecting the cells with the pIRES2-EGFP vector alone, and followed the same protocol as above.

### **2.12 Drugs**

Table 2 outlines the drugs used, the channels they inhibit, dilution vehicles, stock concentrations, half maximal inhibitory concentration (IC<sub>50</sub>) values and their sources. Various concentration-response curves were performed in order to test the minimal and optimal concentrations of the drugs and inhibitors were also tested for their cytotoxicity using LDH assays as described above.

#### 2.13 Statistics

For cell counting experiments, cell volume regulation, and LDH assays data was analyzed using ANOVA with Tukey's post hoc tests, followed by a Students t-test for unpaired values. A P-value of < 0.05 was considered significant.

### **CHAPTER 3: RESULTS**

### 3.1 HBE and CFBE cells express K<sub>v</sub> and K<sub>Ca</sub> channel mRNA.

RNA extraction and RT-PCR were performed on HBE and CFBE cells in order to investigate mRNA expression for various  $K^+$  channels. The PCR transcripts for  $K_v7.1$  (Figure 4A),  $K_v7.5$  (Figure 4B),  $K_v4.1$  (Figure 4C),  $K_v4.2$  (Figure 4D), Kv11.1 (Figure 4F),  $K_{Ca}1.1$  (Figure 4G) and  $K_{Ca}3.1$  (Figure 4H) were all detected for HBE (H) and CFBE (CF) cells at the expected amplicon size (arrow). The PCR transcript for Kv10.1 (Figure 4E) was detected in CFBE cells at the expected size, but not in HBE cells. After repeated attempts using different PCR conditions no transcript was detected for  $K_v4.3$  (Figure 4I) in HBE or CFBE cells; however it was detected in Calu-3 (C) cells at the expected amplicon size. The negative RT samples (-), which consisted of  $H_2O$  alone, did not detect any of the PCR transcripts (Figure 4A-I). All PCR experiments were run for 40 cycles and performed at least 3 times.

### 3.2 HBE and CFBE cells express $K_v7.1$ and $K_v7.5$ protein.

Protein extraction and Western blots were performed on HBE and CFBE cells in order to investigate K<sub>v</sub>7.1 and K<sub>v</sub>7.5 protein expression. Protein was detected for K<sub>v</sub>7.1 at 75 kDa in HBE (+H) and CFBE (+CF) cells; however, when the primary antibody was omitted (-), no protein was detected (Figure 5A). This acted as a negative control, because there was no commercially available blocking peptide for this antibody. Protein was also detected for K<sub>v</sub>7.5 at 116 kDa in both cell lines, and again no protein was detected when the primary antibody was omitted due to the lack of commercially available K<sub>v</sub>7.5 blocking peptide (Figure 5B). Each experiment was performed at least 3 times.

# 3.3 Various $K_{\nu}$ and $K_{Ca}$ channel inhibitors affect cell proliferation in HBE and CFBE cells.

A Coulter Counter was used to measure cell number as a means to assess the contribution of various  $K^+$  channels to cell proliferation in these model cell lines. First, the doubling time of these cells were investigated in order to measure how long it took

before the population of cells entered the M phase of the cell cycle. This is important, since K<sup>+</sup> channels play a role in allowing the cell to progress through the G<sub>1</sub> phase of the cell cycle; therefore, by treating the cells with K<sup>+</sup> channel inhibitors before they divide, they are able to become partially synchronized in this phase (Wonderlin and Strobl, 1996). It must be noted however, that when the doubling time has been reached, it does not necessary mean that all the cells have divided, as some cells of the population may be in other phases as well. Doubling time experiments were performed by plating 200,000 HBE and 64,000 CFBE cells in 6-well plates and letting them grow over 96 hr. They were counted every 24 hr and the log of the cell number was plotted. A line of best fit was calculated, and the slope of that line was used to determine the doubling time (NIH Chemical Genomic Center, 2009). For HBE cells, the doubling time was 29.7 hr and for CFBE cells the doubling time was 31.6 hr (Figure 6). Therefore, for all further cell proliferation experiments, cells were treated with inhibitors 24 hr after they were plated to allow the inhibitors to act before the cells divided and counted 48 hr later.

The drugs used to inhibit the channels of interest are described in Table 2 along with the corresponding channels they act on. Inhibitor concentrations were chosen from previous literature (Roy et al., 2010; Harron et al., 2009) and concentration-response experiments (not shown). HBE cell proliferation was significantly inhibited by XE991, flecainide and TRAM-34 (Figure 7A). XE991 (100 µM) inhibited cell proliferation by 20  $\pm$  4.1% (P < 0.05), flecainide (100  $\mu$ M) inhibited cell proliferation by 37  $\pm$  6.3% (P < 0.05) and TRAM-34 (10  $\mu$ M) inhibited cell proliferation by 27.4  $\pm$  5.4% (P < 0.05), all compared to controls. Chromanol 293B (100 µM), stromatoxin (20 nM), astemizole (3  $\mu$ M), E-4031 (3  $\mu$ M) and paxilline (2  $\mu$ M) had no significant effect on cell proliferation in HBE cells (P > 0.05). CFBE cell proliferation was significantly inhibited by XE991, flecainide, astemizole and TRAM-34 (Figure 7B). XE991 (100 µM) inhibited cell proliferation by  $38.2 \pm 7.9\%$  (P < 0.05), while flecainide (100  $\mu$ M) inhibited cell proliferation by  $55.3 \pm 5.9\%$  (P < 0.05), astemizole (3  $\mu$ M) inhibited cell proliferation by  $31.6 \pm 6.0\%$  (P < 0.05) and TRAM-34 (10  $\mu$ M) inhibited cell proliferation by 27.2  $\pm$ 9.1% (P < 0.05), all compared to controls. 293B (100  $\mu$ M), stromatoxin (20 nM), E-4031 (3 µM) and paxilline (2 µM) had no significant effect on cell proliferation in CFBE cells (P > 0.05). These results suggest that in both cell lines, members of the  $K_v 7$  family other

than  $K_v7.1$  are involved in cell proliferation, since XE991 which inhibits  $K_v7.1$ -7.5 significantly inhibited cell number, and 293B which specifically inhibits  $K_v7.1$  did not. It also suggests that  $K_v4.1$  is involved in cell proliferation in both cell lines since flecainide which inhibits  $K_v4.1$ -4.3 significantly inhibits cell number and stromatoxin which specifically inhibits  $K_v4.2$  does not. Since  $K_v4.3$  channels are not expressed in these cell lines (Figure 4I) flecainide must presumably be acting on  $K_v4.1$ .  $K_{Ca}3.1$  also plays a role in cell proliferation, since TRAM-34 significantly inhibits cell number in both cell lines.  $K_v10.1$  plays a role in cell proliferation in CFBE cells only, since astemizole significantly inhibited cell number. These results concur with our previous findings that HBE cells do not express  $K_v10.1$  mRNA (Figure 4E).

In order to confirm that decreases in cell number were not due to cell death, cell cytotoxicity assays were performed. LDH assays were performed on cells 48 hr following treatment with the drugs that produced a significant decrease in cell number (as seen in Figure 7). Neither application of 100  $\mu$ M XE991, 100  $\mu$ M flecainide, nor 10  $\mu$ M TRAM-34 caused significant cell death in HBE cells (Figure 8A). Similarly, there was no cytotoxicity in CFBE cells following the application of 100  $\mu$ M XE991, 3  $\mu$ M astemizole, or 10  $\mu$ M TRAM-34 (Figure 8B). However, significant cell death was seen with 100  $\mu$ M flecainide. Lower concentrations of flecainide did not inhibit cell proliferation (not shown); therefore, it is likely that the decrease in cell number was due to cytotoxicity rather than a true effect on proliferation and it is unlikely that K<sub>v</sub>4.1 plays a role in proliferation in CFBE cells (see Section 4.2.2). HBE cells did not experience these cytotoxic effects from 100  $\mu$ M flecainide, and perhaps this is because HBE cells are more robust than their CF counterparts, and less easily killed.

# 3.4 Cell proliferation is not affected by the addition of the potential mitogens EGF, IGF-1 or E2.

The above experiments investigated the role of K<sup>+</sup> channels in basal cell proliferation. We were next interested in identifying the role of these channels in mitogenic-stimulated proliferation in HBE and CFBE cells. It has been reported that exogenous EGF (0.5 ng/ml) is required for cell migration and wound healing in both normal and CF bronchial epithelial cell lines, NuLi-1 and CuFi-1, respectively (Trinh *et al.*, 2008); therefore, perhaps it is also important for cell proliferation in HBE and CFBE

cells. However, when cells were treated with increasing concentrations of EGF (0.1, 0.5, or 1 ng/ml for 48 hr), there was no significant increase in cell number (Figure 9A). It has also been reported that insulin-like growth factor-1 (IGF-1), is a powerful mitogen that is known to regulate the cell cycle in many cell systems (Pluteanu and Cribbs, 2011). However, when IGF-1 was applied to HBE and CFBE cells (0.1, 0.5, or 1 ng/ml for 48 hr), cell number did not increase (Figure 9B). Finally, 17β-estradiol (E2) was investigated, as this has been shown to cause the mammary epithelial cancer cell line MCF-7 to proliferate faster than controls (Brooks and Skafar, 2004). However, when HBE and CFBE cells were treated with E2 (0.01, 0.1, and 1 nM for 48 hr), it did not increase cell number (Figure 9C). Therefore, HBE and CFBE cells do not respond to the mitogenic-stimulation of EGF, IGF-1 or E2 and the role of K<sup>+</sup> channels in mitogenstimulated versus basal cell proliferation could not be examined.

# 3.5 Cell proliferation is not affected by the addition of the potential $K_{\nu}7$ channel activator flupirtine maleate.

I was also interested in potentially identifying  $K^+$  channel activators in order to investigate their role in cell proliferation. Flupirtine maleate has been proposed as a  $K_v7.2$ -7.5 activator involved in smooth muscle cells (Yeung *et al.*, 2007); therefore, I hypothesized that the addition of flupirtine maleate to HBE and CFBE cells would increase cell number and in turn increase cell proliferation, due to the activation of  $K^+$  channels involved in the cell cycle. When treated with flupirtine maleate (0.5, 1, and 5  $\mu$ M for 48 hr) cell number did not increase (Figure 10). Therefore, perhaps flupirtine maleate does not activate  $K_v7$  channels in bronchial epithelial cells or activation of these channels does not affect cell proliferation.

## 3.6 HBE cells exhibit an RVD response when exposed to hyposmotic solutions.

Cell volume regulation experiments were performed in order to investigate the K<sup>+</sup> channels involved in the RVD response in HBE cells. Initially, cells were placed in an isosmotic solution that measured  $327.3 \pm 0.46$  mOsM. When HBE cells were switched to a more hyposmotic solution of  $180.3 \pm 0.46$  mOsM, the cells increased in size over the first few minutes, and then reduced their volume towards their initial size. This decrease is known as the RVD response and measured  $22.9 \pm 0.74\%$  when cell size was

normalized to fold change in volume (Figure 11A). When the osmolarity was changed to  $206.6 \pm 0.52$  mOsM in order to represent a less severe hyposmotic shock, the cells increased in size but not to the same extent as in (A) and they exhibited an RVD response of only  $4.72 \pm 0.95\%$  (Figure 11B). Finally, when the osmolarity was switched to  $259.5 \pm 0.70$  mOsM to represent an even less severe hyposmotic shock, the cells showed a much smaller increase in size over the first few minutes and again only exhibited an RVD response of  $3.31 \pm 1.65\%$  (Figure 11C). Therefore, all subsequent experiments pertaining to RVD were performed in hyposmotic solutions of  $180.3 \pm 0.46$  mOsM in order to allow the cells to achieve an RVD response that was measurable and reproducible.

# 3.7 Various pharmacological $K_{\nu}$ and $K_{Ca}$ channel inhibitors affect the RVD response in HBE cells.

In order to investigate the contribution of K<sup>+</sup> channels to the RVD response. inhibitors were added to the hyposmotic solution and the % RVD was measured. The fold change in volume curves for selected inhibitors are shown in Figure 12, while Figure 13 shows a summary of these results. Cells were initially bathed in isosmotic solution (327.3)  $\pm$  0.46 mOsM) and were then switched to hyposmotic solutions (180.3  $\pm$  0.46 mOsM) containing an inhibitor. Inhibitor concentrations were initially chosen from previous literature (Harron et al., 2009), however after comparing these concentrations with each drug's IC<sub>50</sub> values, experiments were re-done at these IC<sub>50</sub> concentrations (Table 2). Results between the two attempts did not vary (not shown); therefore, the lower (IC<sub>50</sub>) values were used for all further experiments. When HBE cells were exposed to XE991  $(0.75 \mu M)$ , which inhibits  $K_v$ 7 channel members, the RVD response decreased from 22.9  $\pm 0.74\%$  to  $5.6 \pm 0.9\%$ , exhibiting a significant 17.3% decrease in RVD (P < 0.05) (Figure 12A and Figure 13). In the presence of 293B (5  $\mu$ M), which inhibits  $K_v$ 7.1, the RVD response decreased from  $22.9 \pm 0.74\%$  to  $5.4 \pm 1.2\%$ , exhibiting a significant 17.5% decrease in RVD (P < 0.05) (Figure 13). In the presence of flecainide (50  $\mu$ M), which inhibits  $K_v4$  channel members, the RVD response decreased from  $22.9 \pm 0.74\%$  to  $21.7 \pm 1.1\%$  (n=19), exhibiting a non-significant 1.2% decrease in RVD (P > 0.05) (Figure 13). When treated with stromatoxin (2 nM), which inhibits K<sub>v</sub>4.2, the RVD response did not change from  $22.9 \pm 0.74\%$  to  $22.9 \pm 2.85\%$  (P > 0.05) (Figure 12B and Figure 13). When exposed to astemizole (1 nM), which can inhibit  $K_v 11.1$ , the RVD

response increased from  $22.9 \pm 0.74\%$  to  $24.6 \pm 3.38\%$ , exhibiting a non-significant 1.7% increase in RVD (P > 0.05) (Figure 13). In the presence of E-4031 (14 nM), which also inhibits  $K_v11.1$ , the RVD response decreased from  $22.9 \pm 0.74\%$  to  $6.3 \pm 1.3\%$ , exhibiting a significant 16.6% decrease in RVD (P < 0.05) (Figure 12C and Figure 13). In the presence of paxilline (2 nM), which inhibits  $K_{Ca}1.1$ , the RVD response decreased from  $22.9 \pm 0.74\%$  to  $5.7 \pm 1.8\%$ , exhibiting a significant 17.2% decrease in RVD (P < 0.05) (Figure 12D and Figure 13). Finally, when exposed to TRAM-34 (20 nM), which inhibits  $K_{Ca}3.1$ , the RVD response decreased from  $22.9 \pm 0.74\%$  to  $9.2 \pm 2.1\%$ , exhibiting a significant 13.7% decrease in RVD (P < 0.05) (Figure 13). Therefore, members of the  $K_v7$  family, in particular  $K_v7.1$ , as well as  $K_v11.1$ ,  $K_{Ca}1.1$  and  $K_{Ca}3.1$  all play a role in regulating cell volume in times of hyposmotic stress.

### 3.8 K<sub>v</sub>7.1 channels affect the RVD response in HBE cells.

Once it was evident that XE991 and 293B had similar effects on the RVD response, it was hypothesized that  $K_v7.1$  was the member of the  $K_v7$  family that played a role in cell volume regulation in times of hyposmotic stress in HBE cells. In order to test this hypothesis, siRNA targeting for  $K_v7.1$  and  $K_v7.5$  was attempted, however this was unsuccessful, as none of the three provided siRNA duplexes decreased the protein expression in HBE cells as compared to controls (Figure 14). Next, pharmacological means were used to test this hypothesis, and cells were initially bathed in isosmotic solution (327.3  $\pm$  0.46 mOsM) and then switched to hyposmotic solutions (180.3  $\pm$  0.46 mOsM) containing XE991 and 293B together (0.75 μM and 5 μM respectively) (Table 2). The RVD response decreased from  $22.8 \pm 0.7\%$  to  $5.2 \pm 1.4\%$ , exhibiting a significant 17.6% decrease in RVD (P < 0.05). Figure 15A represents the fold change in volume curves for this experiment, while Figure 15B represents the graphical summary of these results. This suggests that  $K_v7.1$  is the  $K_v7$  channel member involved in the RVD response, and molecular experiments were then performed to further investigate this conclusion. The pIRES2-EGFP- $\Delta$ N-  $K_v$ 7.1 isoform and the pIRES2-EGFP vector control were transfected into HBE cells and after 36-48 hours the RVD response of these cells was examined. Cells were initially bathed in isosmotic solution (327.3  $\pm$  0.46 mOsM) and then switched to hyposmotic solutions (180.3  $\pm$  0.46 mOsM). The RVD response

decreased from  $29.3 \pm 7.0\%$  in the pIRES2-EGFP vector controls to  $3.94 \pm 1.3\%$  in the pIRES2-EGFP- $\Delta$ N-  $K_v$ 7.1 transfected cells, exhibiting a significant 25.36% decrease in RVD (P < 0.05) (Figure 16). Therefore,  $K_v$ 7.1 plays an important role in regulating cell volume in times of hyposmotic stress.

### 3.9 CFBE cells do not elicit an RVD response when exposed to hyposmotic stress.

Once the involvement of K<sup>+</sup> channels was assessed in the RVD response of HBE cells, CFBE cells were then investigated. After switching CFBE cells from an isosmotic solution (327.3  $\pm$  0.46 mOsmol/L) to a more hyposmotic solution (180.3  $\pm$  0.46 mOsmol/L), it was shown that the cells increased in size, but produced a negligible RVD response that measured 3.03  $\pm$  1.09% (Figure 17A). The osmolarity was then lowered (124.2  $\pm$  0.49 mOsM) to produce a more hyposmotic shock in order to achieve an RVD response in these cells, but again the cells produced a negligible RVD response of 0.68  $\pm$  0.54% (Figure 17B). It is evident however, that CFBE cells swell to a much larger extent when they are exposed to this severe hyposmotic shock. It was therefore concluded that CFBE cells, like CF tracheal epithelial cells, do not elicit an RVD response (Vazquez *et al.*, 2001) and therefore, the dysfunction in their CFTR channel must have an effect on the cell volume regulatory mechanism of RVD.

# 3.10 HBE and CFBE cells do not elicit an RVI response when exposed to hyperosmotic solutions.

Experiments were also performed to investigate the RVI response in both HBE and CFBE cells. Initially, cells were placed in an isosmotic solution that measured 327.3  $\pm$  0.46 mOsmol/L. When HBE cells were switched to a more hyperosmotic solution of 482.3  $\pm$  0.41 mOsM, the cells decreased in size quite quickly; however, they never recovered from this decrease and elicited a negligible RVI response of 1.10  $\pm$  0.7% (Figure 18A). The cells were then exposed to a more severe hyperosmotic shock of 528.5  $\pm$  0.43 mOsM and again elicited a negligible RVI response of 0.67  $\pm$  0.67% (Figure 18B). When CFBE cells were exposed to hyperosmotic solutions of 482.3  $\pm$  0.41 mOsM, they did not produce a measurable RVI response (0.07  $\pm$  0.05%) (Figure 18C). When the osmolarity was changed to create a larger hyperosmotic shock (528.5  $\pm$  0.43 mOsM), the CFBE cells underwent a negligible RVI response measuring 2.25  $\pm$  1.11% (Figure 18D).

Therefore HBE and CFBE cells do not undergo an RVI response when exposed to hyperosmotic stress.




Figure 4. Multiple  $K^+$  channel mRNA transcripts are expressed in HBE and CFBE cells. RT-PCR was performed and detected transcripts in HBE (H) and CFBE (CF) cells for  $K_v$ 7.1 (A),  $K_v$ 7.5 (B),  $K_v$ 4.1 (C),  $K_v$ 4.2 (D),  $K_v$ 11.1 (F),  $K_{Ca}$ 1.1 (G), and  $K_{Ca}$ 3.1 (H). Transcripts for  $K_v$ 10.1 were detected in CFBE cells, but not in HBE cells (E). Transcripts for  $K_v$ 4.3 were not detected in HBE or CFBE cells; however Calu-3 (C) cells did express  $K_v$ 4.3 mRNA (I). No transcripts were detected for the negative RT samples (-). HPRT was used as a positive control in order to test the integrity of the cDNA (not shown). The DNA ladder is shown on the left side of each panel and the expected size for each amplicon is shown by the arrows. The primer sequences and annealing temperatures are listed in Table 3.






Figure 5.  $K_v$ 7.1 and  $K_v$ 7.5 protein are expressed in HBE and CFBE cells. Western blots were performed on total cell lysates and protein was detected for (A)  $K_v$ 7.1 at 75 kDa and (B)  $K_v$ 7.5 at 116 kDa in both HBE (+H) and CFBE (+CF) cells. Negative controls (–) were performed by omitting the primary antibody and no protein was detected in these immuno-blots for either cell line. Details for the primary and secondary antibodies are described in Table 4.



**Figure 6. Cell doubling time for HBE and CFBE cells.** The amount of time it took for cells to double in number was investigated in order to begin proliferation studies. Cells were plated at t=0 and counted every 24 hr for 96 hr, and the log value of the cell number was plotted. The linear regression equation was determined (HBE: y = 0.0101x + 4.9495; CFBE: y = 0.0095x + 4.7574) and the doubling time was calculated by dividing 0.3 by the slope for each cell line (NIH Chemical Genomic Center, 2009). HBE cells had a doubling time of 29.7 hr and CFBE cells had a doubling time of 31.6 hr.

# A HBE



# B CFBE





Figure 7. Contribution of  $K^+$  channels to cell proliferation in HBE and CFBE cells. HBE (A) and CFBE (B) cell number was measured using a Coulter Counter to investigate changes in cell proliferation in the presence of specific and non-specific  $K^+$  channel inhibitors for 48 hr. XE991 (100  $\mu$ M), flecainide (100  $\mu$ M), and TRAM-34 (10  $\mu$ M) inhibited cell proliferation in both HBE and CFBE cells, whereas astemizole (3  $\mu$ M) inhibited cell proliferation in CFBE cells only. Cell number was normalized to control data  $\pm$  standard error of the mean (SEM). Each experiment was run in triplicate on 3 different occasions (n=3). \* represents P < 0.05 when compared to controls, as performed by an ANOVA, followed by a Student's t-test.

# A HBE



# B CFBE






Figure 8. Cell viability following treatment with  $K^+$  channel inhibitors. Inhibitors that caused a significant decrease in HBE and CFBE cell number were assessed with an LDH assay to confirm they were not cytotoxic. The same inhibitors and concentrations were used in the cell proliferation studies from Figure 7. In (A) HBE cells none of the inhibitors caused cell death, however in (B) CFBE cells 100  $\mu$ M flecainide was cytotoxic. LDH absorbance was normalized to control data  $\pm$  SEM. Each experiment was run in triplicate on three different occasions (n=3). \* represents P < 0.05 when compared to controls, as performed by an ANOVA, followed by a Student's t-test.

# A EGF



# B IGF-1



## C E2




Figure 9. The mitogens EGF, IGF-1 and E2 have no effect on cell proliferation in HBE and CFBE cells. HBE (left) and CFBE (right) cell proliferation was measured using a Coulter Counter in the presence of the mitogens (A) EGF, (B) IGF-1 and (C) E2 for 48 hr. There was no evidence of mitogenic-stimulated cell proliferation in either cells line for any of these potential mitogens, for various concentrations. Concentration responses were performed for all the experiments and cell number was normalized to control data  $\pm$  SEM. Each experiment was run in triplicate on three different occasions (n=3).







Figure 10. The potential  $K_v$ 7 activator flupirtine maleate does not affect cell proliferation in HBE and CFBE cells. HBE (left) and CFBE (right) cell proliferation was measured using a Coulter Counter in the presence of the suggested  $K_v$ 7 activator flupirtine maleate for 48 hr. There was no difference in cell number in either cell line, for various concentrations of flupirtine maleate. Concentration responses were performed for all the experiments and cell number was normalized to control data  $\pm$  SEM. Each experiment was run in triplicate on three different occasions (n=3).

## A 180 mOsM







## C 260 mOsM




Figure 11. HBE cells swell in response to hyposmotic shock and then undergo varying degrees of RVD depending on the osmolarity. (A) When switched from an isosmotic solution (327 mOsM) to a hyposmotic solution (180 mOsM), HBE cells increased in volume and then underwent an RVD response of 22.9  $\pm$  0.74% (n=131). (B) When switched from an isosmotic solution (327 mOsM) to a less hyposmotic solution (207 mOsM), HBE cells increased in volume and underwent an RVD response, but to a much smaller degree than above (4.72  $\pm$  0.95%; n=8). (C) When switched from an isosmotic solution (327 mOsM) to an even lower hyposmotic solution (260 mOsM), HBE cells increase in volume (to a lesser extent than with lower osmolarities) and produced an RVD response which was even smaller than in (B) (3.31  $\pm$  1.65%; n=8). Cell volume was normalized to that at t = 0 to represent the fold change in volume means  $\pm$  SEM. ISO=isosmotic; HYPO=hyposmotic; RVD=regulatory volume decrease.




Figure 12. Contribution of various  $K^+$  channels to the RVD response in HBE cells. The RVD response was abolished when the hyposmotic solution was presented with the selective and non-selective inhibitors (A) XE991 (0.75 $\mu$ M; n=17), (C) E-4031 (14nM; n=10) and (D) paxilline (2nM; n=12). The RVD response was not significantly different when the hyposmotic solution was presented with the selective inhibitors (B) stromatoxin (2nM; n=10). Cell volume was normalized to that at t = 0 to represent the fold change in volume means  $\pm$  SEM. \* represents P < 0.05 when compared to controls, as performed by an ANOVA, followed by a Student's t-test. ISO=isosmotic; HYPO=hyposmotic; RVD=regulatory volume decrease.




Figure 13.  $K_v$ 7.1-7.5,  $K_v$ 11.1,  $K_{Ca}$ 1.1 and  $K_{Ca}$ 3.1 play a role in the RVD response in HBE cells. % RVD was measured in the presence of specific and non-specific  $K^+$  channel inhibitors. XE991 (0.75  $\mu$ M; n=17), 293B (5  $\mu$ M; n=14), E-4031 (14 nM; n=10), paxilline (2 nM; n=12), and TRAM-34 (20 nM, n=10) significantly inhibit the RVD response. The RVD response was not significantly different when the hyposmotic solution was treated with flecainide (50  $\mu$ M; n=9), stromatoxin (2 nM; n=10), or astemizole (1 nM; n=16). Cell volume was normalized to that at t = 0 to represent the % RVD  $\pm$  SEM. \* represents P < 0.05 when compared to controls, as performed by an ANOVA, followed by a Student's t-test. RVD=regulatory volume decrease.





Figure 14.  $K_v$ 7.1 and  $K_v$ 7.5 siRNA was unsuccessful at producing significant suppression of respective  $K^+$  channel protein in HBE cells. Western blots were performed to analyze the siRNA knockdown efficiency of (A)  $K_v$ 7.1 and (B)  $K_v$ 7.5 channel protein. Three siRNA duplexes (1-3) were provided and tested against control samples that contained siTrans reagent alone. Neither of the three provided duplex showed a decrease in protein compared to control.








Figure 15.  $K_v$ 7.1 plays a role in the RVD response in HBE cells through pharmacological means. RVD was measured in the presence of the non-specific and specific  $K_v$ 7 channel inhibitors XE991 + 293B (0.75  $\mu$ M and 5  $\mu$ M respectively, n=9). % RVD was significantly lower in HBE cells treated with these inhibitors. Cell volume was normalized to that at t = 0 to represent the fold change in volume means  $\pm$  SEM (A) and the % RVD  $\pm$  SEM (B). \* represents P < 0.05 when compared to controls, as performed by an ANOVA, followed by a Student's t-test. ISO=isosmotic; HYPO=hyposmotic; RVD=regulatory volume decrease.





**Figure 16.** K<sub>v</sub>7.1 plays a role in the RVD response in HBE cells through molecular means. RVD was measured by the suppression of K<sub>v</sub>7.1 channels using the truncated pIRES2-EGFP-ΔN-K<sub>v</sub>7.1 mutation (n=8). % RVD was significantly lower in HBE cells transfected with this dominant-negative mutation. Cell volume was normalized to that at t = 0 to represent the fold change in volume means  $\pm$  SEM (A) and the % RVD  $\pm$  SEM (B). \* represents P < 0.05 when compared to controls, as performed by an ANOVA, followed by a Student's t-test. ISO=isosmotic; HYPO=hyposmotic; RVD=regulatory volume decrease.




Figure 17. CFBE cells do not undergo a significant RVD response when exposed to varying degrees of hyposmotic stress. (A) When switched from an isosmotic solution (327 mOsM) to a hyposmotic solution (180 mOsM), CFBE cells increased in volume, and produced a negligible RVD response of  $3.03 \pm 1.09\%$  (n=11). (B) When switched from an isosmotic solution (327 mOsM) to a more hyposmotic solution (125 mOsM), in order to attempt to elicit an RVD response, CFBE cells showed to increase much more in volume, however they produced a smaller RVD response of  $0.68 \pm 0.54\%$  (n=10). Cell volume was normalized to that at t = 0 to represent fold change in volume means  $\pm$  SEM. ISO=isosmotic; HYPO=hyposmotic; RVD=regulatory volume decrease.




Figure 18. HBE and CFBE cells do not undergo an RVI response when exposed to varying degrees of hyperosmotic stress. (A) When switched from an isosmotic solution (327 mOsM) to a hyperosmotic solution (482 mOsM), HBE cells decreased in volume and elicited a negligible RVI response of  $1.10 \pm 0.7\%$  (n=12). (B) When switched from an isosmotic solution (327 mOsM) to a more hypersmotic solution (529 mOsM), HBE cells decreased in volume and elicited an even more negligible RVI response of  $0.67 \pm 0.67\%$  (n=15). (C) When switched from an isosmotic solution (327 mOsM) to a hyperosmotic solution (482 mOsM), CFBE cells decreased in volume and produced a negligible RVI response of  $0.07 \pm 0.05$  (n=9). (D) When switched from an isosmotic solution (327 mOsM) to a more hyperosmotic solution (529 mOsM), CFBE cells decreased in volume and produced a larger, but still negligible RVI response of  $2.25 \pm 1.11\%$  (n=12). Cell volume was normalized to that at t = 0 to represent fold change in volume means  $\pm$  SEM. ISO=isosmotic; HYPER=hyperosmotic; RVI=regulatory volume increase.

### **CHAPTER 4: DISCUSSION**

K<sup>+</sup> channels play an important role in cell proliferation and cell volume regulation in many different types of epithelial cells (Trinh *et al.*, 2007; vanTol *et al.*, 2007; Roy *et al.*, 2008; Trinh *et al.*, 2008; Harron *et al.*, 2009). Specifically, members of the K<sub>v</sub> and K<sub>Ca</sub> channel family, including K<sub>v</sub>7.1, K<sub>v</sub>7.5, K<sub>v</sub>4.1, K<sub>v</sub>4.2, K<sub>v</sub>4.3, K<sub>v</sub>10.1, K<sub>v</sub>11.1, K<sub>Ca</sub>1.1 and K<sub>Ca</sub>3.1 have been implicated in these physiological processes in a variety of non-epithelial and epithelial cell types (Vazquez *et al.*, 2001; Fernandez-Fernandez *et al.*, 2002; Jensen *et al.*, 2005; Trinh *et al.*, 2007; vanTol *et al.*, 2007; Roy *et al.*, 2008; Trinh *et al.*, 2008; Harron *et al.*, 2009; Jang *et al.*, 2009; Kim *et al.*, 2010). Therefore, it appeared reasonable to assume that members of these particular K<sup>+</sup> channel families were also important in cell proliferation and cell volume regulation in human bronchial epithelial cells. However, the precise molecular nature of the K<sup>+</sup> channels involved in these processes had not been investigated in the two model cell lines chosen for this study.

I chose to carry out my study with the widely used human 16HBE14o- (HBE) and CFBE41o- (CFBE) model cell lines. The HBE cell line is derived from normal bronchial epithelial cells, while the CFBE cell line represents CF bronchial epithelial cells containing the  $\Delta$ F508 CFTR mutation. Although both HBE and CFBE cells have many characteristics of native human bronchial epithelial cells (Ehrhardt et al., 2002; Ehrhardt et al., 2005), they are not primary cultures and therefore do not entirely represent true bronchial epithelial cells. These cell lines are however useful because they are easily maintained and allow for high reproducibility between experiments under appropriate culture conditions. HBE cells develop tight junctions when correctly cultured, are able to become polarized and express functional CFTR protein, which is important when studying normal airway epithelial physiology (Ehrhardt et al., 2002). CFBE cells are homozygous for the  $\Delta$ F508 CF-causing CFTR mutation and also develop tight junctions and form cell layers that are electrically tight (Ehrhardt et al., 2005). These characteristics are also important when studying CF airway epithelial physiology. Both these cell lines represent good models for my study, not only because it required a large number of reproducible cells, but also because as mentioned above they share many similar

characteristics to their native counterparts. Although it would have been ideal to have had access to primary tissue from the human bronchial epithelium, these preparations were not available for my project.

### 4.1 Expression of K<sup>+</sup> channels in HBE and CFBE cells.

Although the most studied airway epithelial ion channels are currently CFTR and ENaC due to the fact that they are the key ion channels involved in airway transepithelial transport,  $K^+$  channels are becoming increasingly studied, as they play an important role in many airway epithelial physiological processes (Bardou *et al*, 2009). Since  $K_v7.1$ ,  $K_v7.5$ ,  $K_v4.1$ ,  $K_v4.2$ ,  $K_v4.3$ ,  $K_v10.1$ ,  $K_v11.1$ ,  $K_{Ca}1.1$  and  $K_{Ca}3.1$  play a functional role in cell proliferation and cell volume regulation in many different cell types; I began this study by confirming their mRNA expression in HBE and CFBE cells. Using PCR, I detected the mRNA expression of  $K_v7.1$ ,  $K_v7.5$ ,  $K_v4.1$ ,  $K_v4.2$ ,  $K_v11.1$ ,  $K_{Ca}1.1$  and  $K_{Ca}3.1$  in HBE cells, while in CFBE cells all of these  $K^+$  channels were also expressed, along with  $K_v10.1$  (Figure 4).

I was unable to detect mRNA expression for K<sub>v</sub>4.3 in either HBE or CFBE cells, however it was detected in another airway epithelial cell line Calu-3, therefore there was not a problem with the chosen primers. The integrity of the cDNA was also tested using the housekeeping gene HPRT and produced distinct amplicons at the correct bp size, signifying good quality cDNA. This channel may not be expressed in these cell lines because the primary transepithelial mechanism in Calu-3 cells is Cl<sup>-</sup> secretion, whereas the dominant transepithelial ion movement in HBE and CFBE cells is more likely Na<sup>+</sup> absorption (Harron *et al.*, 2009). One possibility to explain the lack of K<sub>v</sub>4.3 mRNA expression in HBE and CFBE cells may be that this channel is more important in processes involved in anion secretion.

I was also only able to detect mRNA expression for  $K_v10.1$  in CFBE cells, and not in HBE cells. Again the reason for this is not entirely clear; however, it has been previously reported that this channel is not expressed in some normal tissue but is expressed in their cancerous tissue parallels (Pardo *et al.*, 1999; Hemmerlein *et al.*, 2006). Perhaps this channel plays a larger role in pathophysiological processes rather than in normal physiology, or it may merely reflect a difference between HBE and CFBE cells.

Also, the protein expression of this channel was not investigated, so perhaps there is no protein and solely message for  $K_v 10.1$  in CFBE cells; however further functional studies must be performed to investigate the role of  $K_v 10.1$  in CF airway epithelial cells.

I next wanted to investigate whether the mRNA I detected for my  $K^+$  channels of interest was translated into protein. In this, I was restricted to antibodies that were commercially available; furthermore, many of my chosen  $K^+$  channels have showed to have non-specific antibodies (Cowley lab, unpublished data), therefore I chose to focus on  $K_v7.1$  and  $K_v7.5$ . Through immunoblotting, both  $K_v7.1$  and  $K_v7.5$  protein were detected in HBE and CFBE cells (Figure 5). In summary, HBE and CFBE cells both express  $K_v7.1$ ,  $K_v7.5$ ,  $K_v4.1$ ,  $K_v4.2$ ,  $K_v11.1$ ,  $K_{Ca}1.1$  and  $K_{Ca}3.1$  mRNA, as well as protein for  $K_v7.1$  and  $K_v7.5$ . Furthermore, unlike HBE cells, CFBE cells express mRNA for  $K_v10.1$ . Since I could not investigate the protein expression for the remaining  $K^+$  channels, their expression in these cell lines cannot be confirmed; however, the studies described below do support their expression as functional channels in HBE and CFBE cells.

## 4.2 The activity of K<sup>+</sup> channels in HBE and CFBE basal cell proliferation.

As previously mentioned (see Section 1.6), the relationship between K<sup>+</sup> channel activity and cell proliferation is still not completely understood. However it has been concluded that K<sup>+</sup> channels play a role in mediating the cell cycle since they are required to hyperpolarize the membrane potential (Wonderlin and Strobl, 1996). In order for epithelial cells to regenerate after they are wounded, a major step that must occur is cell proliferation and in order for cell proliferation to take place, the cell must adequately and efficiently progress through the cell cycle. Since it has been reported that K<sup>+</sup> channels are involved in cell-cycle progression, their role in human bronchial epithelial cells is potentially of interest. Reports have suggested that K<sup>+</sup> channels primarily play a role in the progression of the cell through the G<sub>1</sub> phase of the cell cycle (Wonderlin and Strobl, 1996; Ouadid-Ahidouch *et al.*, 2001; Roy *et al.*, 2008); therefore, I first attempted to synchronize HBE and CFBE cells in this particular phase by measuring the doubling time of each cell line. Other experiments have used means such as serum-starvation and flow cytometry analysis, which measures the amount of DNA in the cell and can distinguish

between cell cycle phase, to synchronize cells in G<sub>1</sub> (Gray *et al.*, 1986; Roura-Ferrer *et al.*, 2008; Roy *et al.*, 2008). However, because I did not have access to flow cytometry instruments and the cells began to die when left in serum-free culture media for an extended period of time, it was proposed that another means to partially synchronize these cells in G<sub>1</sub> was to calculate their doubling time. This was performed by performing cell counting assays and treating the cells with pharmacological inhibitors before they doubled. Both cell lines doubled by 32 hours (Figure 6); therefore, I treated them both with K<sup>+</sup> channel inhibitors 24 hours after they were plated. Although this technique may not be as specific as others (as mentioned above), for my purposes it was efficient and yielded reproducible results.

To determine whether the K<sup>+</sup> channels of interest to my study contributed a functional role to basal cell proliferation in HBE and CFBE cells, cell counting experiments using a Coulter Counter were performed as a means to assess proliferation. Pharmacological inhibitors of these specific K<sup>+</sup> channels were applied to the cells in order to investigate the extent that these channels are involved in this physiological process. Differences were apparent between cell lines with regard to which specific K<sup>+</sup> channels were involved. In HBE cells, K<sub>v</sub>7.2-7.5, K<sub>v</sub>4.1 and K<sub>Ca</sub>3.1 channels played a role in basal cell proliferation, while K<sub>v</sub>7.2-7.5, K<sub>v</sub>10.1, and K<sub>Ca</sub>3.1 channels were involved in this process in CFBE cells.

#### 4.2.1 The role of K<sub>v</sub>7 channels in HBE and CFBE cell proliferation.

In both HBE and CFBE cells, members of the K<sub>v</sub>7 channel family other than K<sub>v</sub>7.1 appear to be involved in basal cell proliferation, since XE991 (which inhibits all members of the K<sub>v</sub>7 family) decreased cell proliferation, and chromonal 293B (which specifically inhibits K<sub>v</sub>7.1) did not (Figure 7). This finding is in disagreement with previous literature from the normal and CF bronchial epithelial cell lines NuLi and CuFi, in which K<sub>v</sub>7.1 inhibition did affect cell proliferation, measured by [<sup>3</sup>H]thymidine incorporation. This technique measures DNA synthesis and is another means of assessing cell proliferation and was decreased in the presence of the K<sub>v</sub>7.1 inhibitor clofilium (Trinh *et al.*, 2008). However, this experiment was performed in combination with two other K<sup>+</sup> inhibitors; therefore, the decrease in proliferation that was seen may not be

specifically due to K<sub>v</sub>7.1, or it may reflect differences between the cell lines used in each study. Additionally, clofilium is not as selective as 293B as a K<sub>v</sub>7.1 inhibitor (Manikkham et al., 2002), so despite their conclusions, K<sub>v</sub>7.1 may not actually be involved in cell proliferation in the Trinh study. Since XE991 does have an effect on cell proliferation, suggesting a role for one or all  $K_v7.2-7.5$  channels in this process, further experiments must be performed to delineate specifically which K<sub>v</sub>7 channel member is at work. Although K<sub>v</sub>7.2-7.5 channels are more involved in the central nervous system (CNS) and auditory organs (Robbins, 2001), there is evidence that  $K_v7.5$  plays a role in the proliferation of skeletal muscle cells (Roura-Ferrer et al., 2008). One way to investigate whether K<sub>v</sub>7.5 is also important in human bronchial epithelial cells would be to target the channel with siRNA and examine the effects on cell proliferation. However, since K<sub>v</sub>7.5 can co-assemble with K<sub>v</sub>7.3 (Lerche et al., 2000) and reportedly K<sub>v</sub>7.4 (Bal et al., 2008), simply performing siRNA targeting could be difficult. K<sub>v</sub>7.5 has also been reported to play a role on its own in basal transepithelial anion secretion in Calu-3 cells (Moser et al., 2008), therefore siRNA targeting is plausible. However, as will be mentioned below siRNA targeting for both  $K_v7.1$  and  $K_v7.5$  was attempted for several months during this project but were unsuccessful. Although K<sub>v</sub>7.5 has the ability to function on its own, there is also the possibility that it may form a hetermeric complex with  $K_v 7.3$  or  $K_v 7.4$ . However, although I did not detect mRNA expression for  $K_v 7.3$  in HBE or CFBE cells, they do express  $K_v7.2$  and  $K_v7.4$  channels (Moser *et al.*, 2008), therefore in order to investigate the role of  $K_v$ 7.5 in cell proliferation it must be noted that this channel may be forming a heteromeric complex with  $K_v$ 7.4. Future experiments could include co-immunoprecipitation in order to pull down this heteromeric complex and investigate it's molecular properties. This study represents the first time K<sub>v</sub>7.5 channels have been examined in human bronchial epithelial cell proliferation, and further investigation may delineate a role for this channel in this process.

### 4.2.2 The role of K<sub>v</sub>4, K<sub>v</sub>10 and K<sub>v</sub>11 channels in HBE and CFBE cell proliferation.

In HBE cells,  $K_v4.1$  appears to play a role in cell proliferation since flecainide (which inhibits  $K_v4.1-4.3$ ) decreased cell number and stromatoxin (which selectively inhibits  $K_v4.2$ ) did not (Figure 7). Since  $K_v4.3$  mRNA was not detected in either cell line,

flecainide is presumably acting on K<sub>v</sub>4.1 to inhibit cell proliferation in HBE cells. These results are in agreement with reports from studies in both cancerous gastric cells and mammary epithelial cells, which implicate K<sub>v</sub>4.1 in cell proliferation using siRNA targeting (Jang et al., 2009; Kim et al., 2010). A decrease in cell number was also shown in CFBE cells that were treated with flecainide but not stromatoxin; however when cytotoxicity assays were performed I discovered that this effect was due to inhibitorinduced cell death (Figure 7 and 8). Therefore, perhaps  $K_v4.1$  is playing a role in cell proliferation in CFBE cells, but maybe CFBE cells are not as robust as HBE cells in terms of their membrane integrity and overall survival due to their defective CFTR protein. This may cause the presence of flecainide to kill the cells and mask any effect  $K_{\nu}4.1$  channels may have on cell proliferation. Lower dosages of flecainide were used but they did not induce a decrease in cell number, therefore in order to investigate the role of K<sub>v</sub>4.1 in CFBE cells it may be necessary to use different pharmacological inhibitors or to move away from pharmacological means all together, which may be causing cell death, to more molecular means such as siRNA targeting. Another notable K<sub>v</sub>4 channel antagonist is bupivacaine, however this inhibitor also acts on members of the 2-pore domain family of K<sup>+</sup> channels as well as certain Na<sup>+</sup> channels (Harron *et al.*, 2008), therefore I opted for flecainide due to its relative selectivity. In summary, a role for K<sub>2</sub>4.1 is apparent for cell proliferation in HBE cells, however further investigation must be performed in CFBE cells to investigate whether this channel is also important in this process, or if it simply is not involved in cell proliferation in CF airway epithelial cells.

In CFBE cells,  $K_v 10.1$  appears to play a role in cell proliferation since astemizole decreased cell number; however this inhibition was not seen in HBE cells (Figure 7). This finding is in agreement with previous reports in MCF-7 cells (Roy *et al.*, 2008), which also showed that cell proliferation was significantly reduced in the presence of astemizole. Since  $K_v 10.1$  mRNA was not expressed in HBE cells, it is not surprising that astemizole did not decrease cell proliferation in this cell line. Therefore it is likely that there is a role for  $K_v 10.1$  in cell proliferation in CFBE cells. The same study by Roy and colleagues also reported that  $K_v 11.1$  did not play a role in cell proliferation when it was inhibited by E-4031 and in this study, treating HBE and CFBE cells with this  $K_v 11.1$  inhibitor had no affect on cell proliferation (Figure 7). Therefore, perhaps this channel is

not as important in cell proliferation as  $K_v 10.1$ , and as I will discuss later in this chapter, it may be more crucial to other physiological processes pertaining to airway epithelial cells.

## 4.2.3 The role of $K_{Ca}1.1$ and $K_{Ca}3.1$ channels in HBE and CFBE cell proliferation.

Finally, the  $K_{Ca}1.1$  inhibitor paxilline did not have any significant effect on cell proliferation in either cell line, while TRAM-34, which inhibits  $K_{Ca}3.1$  channel activity, significantly decreased cell proliferation in HBE and CFBE cells (Figure 7). Previous literature from both MCF-7 (Roy *et al.*, 2010) and NuLi cell lines (Trinh *et al.*, 2008) both concluded this same result for TRAM-34. However, the results for the NuLi cell line, another model of bronchial epithelial cells, were again in combination with two other  $K^+$  channel inhibitors, therefore it is impossible to determine precisely which channels are playing a role. However, it is unlikely that  $K_v7.1$  is important in cell proliferation in their study (Trinh *et al.*, 2008) because they used a non-selective  $K_v7.1$  inhibitor (clofilium) and I believe that  $K_{Ca}3.1$  is more important to cell proliferation in NuLi and CuFi cell lines, which is in agreement to what I have shown in HBE and CFBE cells.

## 4.2.4 Limitations in the selectivity of K<sup>+</sup> channels for cell proliferation studies.

A major drawback when studying the role of K<sup>+</sup> channels in cell proliferation relates to the specificity of each K<sup>+</sup> channel antagonist, meaning that when higher concentrations of inhibitors are used there is a greater chance that they may be acting on different transport proteins. For example, 293B selectively inhibits K<sub>v</sub>7.1 channels when used at a specific IC<sub>50</sub> value; however increasing this concentration also causes this antagonist to inhibit CFTR channels (Bachmann *et al.*, 2001). When experiments are performed to investigate ion channel currents within the cell, the IC<sub>50</sub> values are usually measured to determine the concentration of antagonist that will provide 50% inhibition of a particular channel, in order to be confident that the correct channel is under examination. However, unlike the study of ion channel currents, cell proliferation assays require much higher concentrations of inhibitors in order to elicit an effect (Wonderlin and Strobl, 1996). This is likely due to the addition of serum to the culture medium

during proliferation experiments, but not to the solutions used during current recordings. It has been suggested that the inhibitory drugs in question may bind to the serum in the culture medium, causing a decrease in the overall potency of the inhibitor (Wonderlin and Strobl, 1996). Since HBE and CFBE cells were treated in culture media containing 1% serum, due to the fact that treating them in serum-free media for 48 hr caused the cells to die, this is the main reason why the concentrations I chose for the cell proliferation experiment were much higher than their IC<sub>50</sub> values shown in Table 2. Previous literature reports and concentration-response experiments were also used to select the optimal concentrations of pharmacological inhibitors for these studies, and from these results I used the lowest dose that produced a significant response as compared to controls. Although this approach is not perfect, when culture conditions were kept consistent it created significant and reproducible results, and was used as a guide to measure cell proliferation.

## 4.2.5 Proposed mechanism for the role of $K^+$ channels in cell proliferation in airway epithelial cells.

Although it has been concluded that hyperpolarization of the cell through the efflux of K<sup>+</sup> ions drives the cell through the G<sub>1</sub> phase of the cell cycle, the exact mechanism behind how this hyperpolarization can directly cause cells to proliferate is still not completely clear. I propose a model in Figure 19 in which the potential contribution of various K<sup>+</sup> channels is suggested to regulate the cell cycle and induce cell proliferation. These  $K^+$  channels include members of the  $K_v$ 7 family,  $K_v$ 4.1 and  $K_{Ca}$ 3.1 in HBE cells, as well as these channels and potentially K<sub>v</sub>10.1 in CFBE cells. This model begins with the efflux of K<sup>+</sup> ions through activated K<sup>+</sup> channels, which then causes the cell membrane to become hyperpolarized. Activation of these K<sup>+</sup> channels may occur through an increase in [Ca<sup>2+</sup>]<sub>i</sub>, cAMP activity, and/or the involvement of mitogens. This hyperpolarization then creates a driving force for Ca<sup>2+</sup> ions to enter the cell through open Ca<sup>2+</sup> channels on the cell membrane. This influx of Ca<sup>2+</sup> increases the [Ca<sup>2+</sup>]<sub>i</sub>, which in turn increases the activity of Ca<sup>2+</sup>-dependent kinases within the cell, including Ca<sup>2+</sup>/calmodulin-dependent kinases. These kinases regulate the activity of cyclins and cyclin-dependent kinases, which not only allow the cell to progress through G<sub>1</sub>, but can also regulate cell cycle progression at various transition checkpoints. Therefore,

inhibiting these K<sup>+</sup> channels depolarizes the cell membrane, which can disrupt cell cycle progression (Wonderlin and Strobl, 1996). Although this is just a proposed mechanism, it may suggest how K<sup>+</sup> channel activity relates to cell proliferation in normal and CF bronchial epithelial cells, which can provide further insight into the mechanics involved in epithelial wound repair.

## 4.3 The activity of K<sup>+</sup> channels in mitogenic- and activator-stimulated cell proliferation.

Although one of the main objectives of this project was to study the role that K<sup>+</sup> channels played in basal cell proliferation, I was also interested in discovering any novel roles that various mitogens or K<sup>+</sup> channel activators might play in cell proliferation within HBE and CFBE cells. Moreover, if these potential mitogens and activators do affect cell proliferation, how was K<sup>+</sup> channel activity involved? Using a Coulter Counter to measure cell proliferation, I chose to investigate the mitogens EGF, IGF-1 and E2, as well as the K<sub>v</sub>7 channel activator flupirtine maleate due to their implications in a variety of previous literature described below, in attempt to find a stimulator for cell proliferation in HBE and CFBE cells.

## 4.3.1 The role of mitogen-stimulated cell proliferation in HBE and CFBE cells.

In order to investigate the role of K<sup>+</sup> channels in mitogen-stimulated cell proliferation in HBE and CFBE cells, I first exposed cells to EGF for 48 hr and found that there was no significant increase in cell proliferation (Figure 9). Although it has been previously shown that EGF stimulates cell proliferation in a variety of cells types, including esophageal and prostatic epithelial cells, and granulosa cells (Gospodarowicz *et al.*, 1977; Ilio *et al.*, 1995; Rahman *et al.*, 2010), it has also been shown that EGF does not affect cell proliferation in airway epithelial cells (Trinh *et al.*, 2008). This group concluded that EGF is an important mediator of cell migration, but not cell proliferation, in the epithelial wound repair process in human airway epithelial cells (Trinh *et al.*, 2008). Therefore perhaps EGF is a potent mitogen in some cell systems and not in others. However, even when not playing a role in cell proliferation in a particular cells system, perhaps its still involved in other physiological processes in that cell.

I was also interested in IGF-1 and E2, which are reportedly potent mitogens that play important roles in mediating the cell cycle in various cell types, including smooth muscle cells and mammary epithelial cells (Brooks and Skafar, 2004; Pluteanu and Cribbs, 2011). Airway epithelial cells express the IGF-1 receptor (IGF-1R) and this mitogen has been reported as playing a role in airway remodeling (Chihara *et al.*, 1996). These cells also express the E2 receptor, ERα, and this mitogen is involved in ion transport within the lungs (Coakley *et al.*, 2008). I found however that in HBE and CFBE cells, these mitogens did not increase cell number, suggesting that perhaps they simply are not important mediators of cell proliferation in human bronchial epithelial cells (Figure 9). Further investigation into whether these potential mitogens are involved in processes important to airway epithelial cells must occur and may be useful in understanding the mechanisms behind epithelial wound repair and CF.

## 4.3.2 The role of $K_{\nu}7$ channel activator-stimulated cell proliferation in HBE and CFBE cells.

The putative K<sub>v</sub>7 channel activator flupirtine maleate was then used to examine HBE and CFBE cell proliferation, as it has been previously reported that it plays a role in K<sub>v</sub>7 channel activation in the vascular tone of murine blood vessels (Yeung et al., 2007). I found however, that this potential activator did not increase cell proliferation in either cell line (Figure 10). Two potential interpretations were concluded from this experiment; firstly, perhaps flupirtine maleate simply does not activate K<sub>v</sub>7 channels in human bronchial epithelial cells, or secondly, perhaps the activation of K<sub>v</sub>7 channels in these cell lines does not have a direct effect on cell proliferation. Previous literature has also reported that when airway epithelial wound repair was studied in NuLi and CuFi cells, the K<sub>ATP</sub> channel activator pinacidil did not increase cell proliferation, although it did increase cell migration in both cell lines (Trinh et al., 2008). Therefore, although the inhibition of K<sup>+</sup> channels causes a significant decrease in bronchial epithelial cell proliferation, perhaps the activation of these channels does not directly cause an increase in cell number. However further studies would be useful to determine if this is true for all K<sup>+</sup> channels in HBE and CFBE cells lines, by using different potential K<sup>+</sup> channel activators.

## 4.4 The activity of $K^{\dagger}$ channels in the regulation of HBE cell volume in times of hyposmotic stress.

Another important function of airway epithelial cells is their ability to regulate their volume in times of altered intracellular and extracellular osmolarities. Cell volume regulation is a very important physiological process, and is related to many other airway epithelial cell functions, including ion transport and cell proliferation (Lang *et al.*, 1998). In airway epithelial cells, disruptions in the osmolarity of the PCL volume can lead to changes in cell volume, which occur in order to maintain a state of homeostasis (Lock and Valverde, 2000). Cell volume must also double as the cell progresses through the cell-cycle so that after mitosis the daughter cells are able to be the same size as their original parent cell (Wang *et al.*, 2002b). Therefore, cell volume regulation is very important and must be further examined in order to increase the understanding of normal and pathophysiological conditions concerning airway epithelial cells.

In times of hyposmotic stress, cells swell in size due to a fast influx of water that attempts to equilibrate the intra- and extracellular osmolarities. This process activates K<sup>+</sup> and Cl<sup>-</sup> channels on the cell membrane and through the subsequent efflux of these ions, the cell will shrink back down to its original size which is defined as the RVD response (Lang et al., 1998). The activation of these K<sup>+</sup> channels in the regulation of cell volume has been studied in other cell systems, including Calu-3 and MCF-7 cells (vanTol et al., 2007; Harron et al., 2009), however in human bronchial epithelial cells it is not entirely known as to which K<sup>+</sup> channels are specifically involved in this process. Using the cell volume protocol explained in Section 2.9, my results show that HBE cells do elicit an RVD response when exposed to hyposmotic stress, which is in agreement with previous reports that demonstrated the involvement of this cell line in the regulation of cell volume and the RVD process (Fernandez-Fernandez et al., 2002). However, in the experiments by Fernandez-Fernandez and colleagues, they exposed cells to hyposmotic osmolarities of 215 mOsM, which did not elicit a measurable RVD response in my HBE cells (Figure 11). The only measurable response I saw was when HBE cells were exposed to 180 mOsM solutions, and therefore I used this osmolarity for all further experiments to elicit a measurable and reproducible RVD response. When pharmacological inhibitors were applied to the 180 mOsM hyposmotic solution, it was shown that the  $K_v$  and  $K_{Ca}$ channels that played an important role in the RVD response in HBE cells were K<sub>v</sub>7.1,

 $K_v11.1$ ,  $K_{Ca}1.1$  and  $K_{Ca}3.1$ . The inhibitor concentrations that were used for these experiments were similar to the specific inhibitors  $IC_{50}$  value, since the experimental protocol for cell volume is much more similar to that performed to measure current recordings, than cell proliferation is, due to the fact that serum is not present and since the acute action of the  $K^+$  channels of interest are being investigated rather than their chronic action, which was examined in the previous cell proliferation studies.

#### 4.4.1 The role of K<sub>v</sub>7 channels in HBE cell volume regulation.

XE991 was used to assess the role of K<sub>v</sub>7 family members in the RVD response in HBE cells, and it significantly decreased the % RVD in this cell line (Figure 12 and 13). Previous reports have also shown that XE991 inhibits the RVD response in other cell types, including MCF-7 and Calu-3 cells (vanTol et al., 2007; Harron et al., 2009). I next wanted to further investigate which specific K<sub>v</sub>7 channel member was involved, and used chromanol 293B, which significantly inhibited the RVD response in HBE cells (Figure 13). Unlike in Calu-3 cells, where K<sub>v</sub>7.1 did not have an effect (Harron et al., 2009), the inhibition of the RVD response by 293B has been seen in MCF-7 cells (vanTol et al., 2007), as well as in murine tracheal cells (Lock and Valverde, 2000). Although it was still not clear whether  $K_v$ 7.1 is the sole  $K_v$ 7 channel involved in the RVD response, the similarity between the reduction in % RVD between XE991 and 293B suggests that it indeed is. To further investiate this I used molecular knockdown experiments. I initially had hoped to test this hypothesis using siRNA techniques; however, after several months of unsuccessful attempts to produce a decrease in protein expression for K<sub>v</sub>7.1 and K<sub>v</sub>7.5 with siRNA (Figure 14), I decided to use a dominant-negative mutation to solve this problem. Before this, I first exposed HBE cells to hyposmotic solutions that contained both XE991 and 293B together and found that there was no additive effect on the % RVD, pointing towards the role for  $K_v7.1$  in the RVD response (Figure 15). I then used a truncated isoform of K<sub>v</sub>7.1, in which the NH<sub>2</sub>-terminal end and the first one-third of the S1 segment was removed (Jiang et al., 1997; vanTol et al., 2007). These experiments demonstrated that when HBE cells were transfected with this truncated K<sub>v</sub>7.1 isoform (pIRES2-EGFP- $\Delta$ N-K<sub>v</sub>7.1) and exposed to hyposmotic conditions, they failed to elicit a measurable RVD response compared to the pIRES2-EGFP vector control (Figure 16).

From these results, I conclude that  $K_v7.1$  is primarily involved in the RVD response in HBE cells. Although  $K_v7.2$ , 7.4 and 7.5 are also expressed in HBE cells, without adequate experiments that target these channels specifically, their potential role in the RVD response cannot be examined. Since murine  $K_v7.5$  channels alone have been implicated in changes in cell volume in *Xenopus* oocytes (Jensen *et al.*, 2005), this member of the  $K_v7$  channel family may play an important role in HBE cells. Because  $K_v7.5$  siRNA studies were unsuccesful, future experiments using a dominant-negative variant of  $K_v7.5$  could be useful to describe the role that this channel plays in the regulation of HBE cell volume and the RVD response. Recently, mice models that contain a dominant negative mutation in the  $K_v7.5$  pore have been created (Tzingounis *et al.*, 2010), and hopefully this is only the beginning in the investigation into this less understood  $K^+$  channel.

#### 4.4.2 The role of K<sub>v</sub>4, K<sub>v</sub>10 and K<sub>v</sub>11 channels in HBE cell volume regulation.

I next looked at the role that  $K_v4.1$  and  $K_v4.2$  play in the RVD response, since it has been previously reported that  $K_v4.1$  is an important player in the RVD process in Calu-3 cells (Harron *et al.*, 2009). This group also suggested that  $K_v4.2$  did not play an important role in this process (Harron *et al.*, 2009). I discovered that in HBE cells, the pharmacological inhibition of  $K_v4.1$  and  $K_v4.2$  by flecainide and stromatoxin respectively did not affect the RVD response compared to controls (Figure 12 and 13). Since I saw no effect of  $K_v4.2$  in cell proliferation either, this channel is clearly involved in other respiratory epithelial processes, perhaps similar to those proposed in alveolar epithelial cells, such as  $K^+$  recycling into the lumen (Lee *et al.*, 2003) and oxygen sensing (O'Grady and Lee, 2005). A second explanation could be that since there is no role for this channel in either of these two physiological processes and protein expression could not be examined in HBE cells, perhaps  $K_v4.2$  is not truly expressed in this cell line. On the other hand,  $K_v4.1$  does presumably play a role in cell proliferation; therefore although its protein expression was not examined it does seem to have a functional role in HBE cells, however not in terms of regulating the RVD response.

I next wanted to look at the role  $K_v10.1$  and  $K_v11.1$  play in the RVD response. Although  $K_v10.1$  mRNA was not expressed in HBE cells, I used astemizole to primarily act as a positive control and found that the addition of astemizole (at concentrations near it's IC<sub>50</sub> value) to the hyposmotic solution did not significantly affect the RVD response (not shown). This supported my finding that K<sub>v</sub>10.1 is not expressed in HBE cells. I next wanted to test whether astemizole can also inhibit K<sub>v</sub>11.1 channels, since it has been reported that a much lower IC<sub>50</sub> value can also inhibit this channel (Cavalli *et al.*, 2002). I again found that this did not significantly affect the RVD response in HBE cells (Figure 13), which suggests that astemizole is perhaps more selective towards K<sub>v</sub>10.1 than K<sub>v</sub>11.1. Unlike K<sub>v</sub>10.1, K<sub>v</sub>11.1 mRNA is expressed in HBE cells, and has been previously implicated in playing a role in the RVD response in MCF-7 cells (Roy *et al.*, 2008). Using the same pharmacological inhibitor for K<sub>v</sub>11.1, E-4031 that was used by Roy and colleagues, I found that in HBE cells it also reduced the % RVD (Figure 12 and 13). Therefore, I conclude a role for K<sub>v</sub>11.1 in the regulation of cell volume in times of hyposmotic stress in HBE cells.

### 4.4.3 The role of $K_{Ca}1.1$ and $K_{Ca}3.1$ channels in HBE cell volume regulation.

I finally investigated the role that  $K_{Ca}1.1$  and  $K_{Ca}3.1$  play in the RVD response. It has been previously reported that  $K_{Ca}1.1$  and  $K_{Ca}3.1$  mediate the RVD response in bronchial and tracheal epithelial cells respectively (Vazquez *et al.*, 2001; Fernandez-Fernandez *et al.*, 2002). My results confirmed these previous reports by demonstrating that  $K_{Ca}1.1$  did play a role in the RVD response, since pharmacological inhibition of this channel with paxilline caused a significant reduction in the % RVD (Figure 12 and 13). I also found that inhibiting  $K_{Ca}3.1$  with TRAM-34 also significantly reduced the % RVD (Figure 13). Although  $K_{Ca}3.1$  is primarily involved in the RVD response of tracheal epithelial cells, perhaps it is also important in HBE cells. There is a smaller reduction in % RVD when TRAM-34 was used than there is for paxilline, therefore perhaps  $K_{Ca}3.1$  is playing a less important role than  $K_{Ca}1.1$  in mediating cell volume in times of hyposmotic stress in HBE cells, which would support the findings by Vazquez and Fernandez-Fernandez.

## 4.4.4 Limitations in the study of K<sup>+</sup> channels and the RVD response in HBE cells.

Unlike the limitations that were described for the study of K<sup>+</sup> channels and cell proliferation in relation to the selectivity of the K<sup>+</sup> channel inhibitors, the selectivity for the antagonists used in the study of cell volume and the RVD response closely reflect the IC<sub>50</sub> values of the inhibitors involved. Since the cells are perfused in solutions that do not contain serum, the higher inhibitor concentration was not needed. However, a major limitation to this study, which is also pertinent to the cell proliferation study, is the inability to complete successful siRNA experiments. Without siRNA targeting, my conclusions are not as strong, and questions continue to arise about whether the pharmacological findings are truly real because direct targeting of a channel at the molecular level is much more selective that at the pharmacological level. Another limitation, and one that continuously arises when using model cell lines, is how representative the model cells are to native human bronchial epithelial cells. Cultured cells can lose particular phenotypes specific to native cells (Ehrhardt et al., 2002, 2005) However as mentioned above, these cell lines do contain many of the same characteristics as native cells and have been shown to be close representative models to their native cell counterparts. Finally, the expression of accessory subunits, including members of the minK family, may alter the findings for both cell proliferation and cell volume regulation; however, I did not investigate the expression of these subunits in HBE or CFBE cell lines. For example, the IC<sub>50</sub> value for XE991 is higher for K<sub>v</sub>7.1 channels that coassemble with minK proteins (Wang et al., 2000), therefore it must be determined if this co-assembly between K<sub>v</sub>7.1 and minK occurs in bronchial epithelial cells. Coimmunoprecipitation could then be performed if a co-assembly is discovered, in order to better understand the molecular nature of these complement proteins.

# 4.4.5 Proposed mechanism for the role of $K^{\dagger}$ channels in cell volume regulation and the RVD response in HBE cells.

The mechanism behind how HBE cells elicit their RVD response is not completely clear; however, there are different theories as to how this occurs. The most relevant theory involves a particular role for Ca<sup>2+</sup> in order to initiate this response and is shown in Figure 20. In human bronchial epithelial cells, it was reported that an increase in [Ca<sup>2+</sup>]<sub>i</sub> was observed after hyposmotic cell swelling (Fernandez-Fernandez *et al.*,

2002), and was then suggested that TRPV4, a non-selective cation channel may be the entry pathway for  $Ca^{2+}$  into the cell, which then activates  $K_{Ca}1.1$  channels, which are responsible for mediating the RVD response in bronchial epithelial cells (Fernandez-Fernandez et al., 2002; Becker et al., 2005). Since K<sub>Ca</sub>3.1 also seems to be playing a role in my cell line, this increase in [Ca<sup>2+</sup>]<sub>i</sub> may be activating this channel as well. Although I have not personally investigated TRPV4 in HBE or CFBE cells, its expression has been previously reported in both cell lines (Fernandez-Fernandez et al., 2008). This activation of K<sub>Ca</sub> channels allows for the efflux of K<sup>+</sup> ions from the cell, initiating the RVD response. This efflux of K<sup>+</sup> ions would then hyperpolarize the cell membrane and create a driving force for Ca<sup>2+</sup> entry into the cell through open Ca<sup>2+</sup> channels. This would then increase the  $[Ca^{2+}]_i$  and activate  $K_{Ca}$  channels like  $K_{Ca}1.1$  and  $K_{Ca}3.1$ , and also cause the membrane to depolarize, activating  $K_v$  channels like  $K_v7.1$  and  $K_v11.1$  on the cell membrane which would all cause the efflux of K<sup>+</sup> ions and create the RVD response. It has been shown that in tracheal epithelial cells, when TRPV4 was knocked down, it abolished the  $K_{Ca}3.1$  current involved in mediating the RVD response in these cells (Arniges et al., 2004). This experiment was also performed in HBE cells (Fernandez-Fernandez et al., 2008) and showed a decrease in K<sub>Ca</sub>1.1 current when TRPV4 was knocked down. This strongly suggests that the candidate for Ca<sup>2+</sup> influx into these cells is TRPV4, and further investigation into the specific signaling mechanism that occurs once Ca<sup>2+</sup> has entered the cell and leads to the RVD response must be performed.

## 4.5 The regulation of CFBE cell volume regulation in times of hyposmotic stress.

I next wanted to investigate whether CFBE cells elicited an RVD response. Previous literature has suggested that these cells do not undergo the RVD process due to their dysfunctional CFTR protein (Vazquez *et al.*, 2001), however I wanted to use extreme hyposmotic shock to examine if these reports had just not tried low enough osmolarities to induce a response. However, I was unable to elicit an RVD response in 125 or 180 mOsM hyposmotic solutions (Figure 17). In human tracheal epithelial cells, it was shown that the  $K^+$  channel mediating the RVD response was  $K_{Ca}3.1$ , and that although the CF human tracheal epithelial cells containing the homozygous  $\Delta$ F508 CFTR mutation showed functional  $K_{Ca}3.1$  activity, the channel was not activated in response to

hyposmotic-induced swelling (Vazquez et al., 2001). It is still not clear what the link is between CFTR and the K<sup>+</sup> channels involved in the RVD response, however multiple hypotheses have been suggested. First, it has been reported that ATP may relate the two, since ATP is released when cells are exposed to hyposmotic shock, and this release may be increased by CFTR through the efflux of intracellular Cl (Hazama et al., 2000). Although this is a possibility, it has yet to be proved as to how this is related to K<sup>+</sup> channel activation since this hypothesis is directed towards the activation of Cl<sup>-</sup> channels and the RVD response (Vazquez et al., 2001). A second hypothesis is related to Ca<sup>2+</sup>, and proposes that CFTR may be required for Ca<sup>2+</sup> entry into the cell under times of hyposmotic stress (Reinlib et al., 1992). Although it is not exactly known as to how this occurs, it has been reported that there is a dysfunction in the activation of the K<sup>+</sup> channels involved in the RVD response via the swelling-mediated pathway (Arniges et al., 2004). The lack of functional CFTR in CF airway epithelial cells may have a direct or in-direct affect on the Ca<sup>2+</sup> entry protein in HBE cells, since CFTR is able to modulate other transport proteins through changes in post-transitional regulation or protein expression (Schwiebert et al., 1999; Kunzelmann, 2001) This hypothesis has been expanded upon, and it is currently thought that there is a dysfunction in the Ca<sup>2+</sup> entry into the cell via TRPV4 in CF airway epithelial cells (Arniges et al., 2004). Arniges and colleagues showed that both tracheal and bronchial epithelial cell lines did not RVD in the presence of hyposmotic stress and also did not display an increase in [Ca<sup>2+</sup>]; when exposed to these conditions. These cells did however express TRPV4 mRNA, and when TRPV4 was activated by  $4\alpha$ -phorbol 12, 13-didecanoate ( $4\alpha$ -PDD), the RVD response was restored as well as the [Ca<sup>2+</sup>]<sub>i</sub>. Therefore, they concluded that there is some sort of dysfunction in the TRPV4 channel in CF cells that does not allow for adequate Ca<sup>2+</sup> influx, causing K<sub>v</sub> and K<sub>Ca</sub> channels to not activate and elicit an RVD response. It has been proposed that stimuli that cause an increase in [Ca<sup>2+</sup>]<sub>i</sub>, such as cell swelling by hyposmotic stress, causes an decrease in Na<sup>+</sup> absorption (Arniges et al., 2004). Therefore the decrease in induced Ca<sup>2+</sup> signal due to a dysfunction in the TRPV4 channel may lead to an increase in Na<sup>+</sup> absorption, a hallmark of CF. This work may one day help better understand the consequences of hyposmotic stress on CF airway epithelial cells.

## 4.6 The regulation of HBE and CFBE cell volume regulation in times of hyperosmotic stress.

Although one of the main objectives of my project was to investigate the role of K<sup>+</sup> channels in the RVD response, I was also interested in determining whether HBE and CFBE cells were involved in regulating their cell volume in times of hyperosmotic stress. In this process, cells shrink in size due to the efflux of water that attempts to equilibrate the intra- and extracellular osmolarities. The cell then swells back up to original size, known as an RVI response. It has been previously reported that Calu-3 cells do not undergo this RVI response, because unlike the activation of K<sup>+</sup> and Cl<sup>-</sup> channels that are involved in the RVD process, the RVI response activates Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> co-transporters, Na<sup>+</sup>/H<sup>+</sup> exchangers and some Na<sup>+</sup> channels (Lang et al., 1996; Harron et al., 2009). Since Calu-3 cells are mainly involved in Cl secretion, and do not express functional ENaC, it is not unexpected that these cells do not undergo an RVI response (Harron et al., 2009). However, since HBE and CFBE cells do play a role in Na<sup>+</sup> absorption, they may elicit an RVI response in times of hyperosmotic stress. However, contrary to my hypothesis, I found with varying degrees of hyperosmotic shock, neither HBE nor CFBE cells elicited this response (Figure 18). Therefore, further examination behind the mechanisms of the RVI response must be performed to fully understand this process, and perhaps the ability of HBE and CFBE cells to play a role in Na<sup>+</sup> absorption does not mean that they are involved in every physiological process mediated by Na<sup>+</sup> transport proteins.

# 4.7 The significance of $K^+$ channel activity in cell proliferation and cell volume regulation in respiratory epithelial physiology.

A better understanding of the functions of airway epithelial cells will allow us to gain further insight into how they are involved in human physiology. This study investigated how two human airway epithelial cell lines are involved in cell proliferation and cell volume regulation, and more specifically, how K<sup>+</sup> channels affect these physiological processes. Although this is just an investigation on 9 of the approximately 40 K<sup>+</sup> channels that are in the airway epithelium, it is an attempt to begin delineating the role of these channels in this system. It is also an informative comparison as to how normal and CF bronchial epithelial cells differ in not only their K<sup>+</sup> channel physiology, but also in physiological processes that are important to their functioning. It is my hope

that there will be future reports on  $K^+$  channel involvement in the airways, and that this work will help to better characterize their place in human physiology and perhaps lead the way for potential therapeutic  $K^+$  channel targeting for airway diseases such as CF.




Figure 19. Schematic model illustrating the mechanisms involved in  $K^+$  channel mediated cell proliferation in HBE and CFBE cells. The efflux of  $K^+$  ions through activated  $K^+$  channels, including  $K_v$ 7.2-7.5,  $K_v$ 4.1,  $K_v$ 10.1 and  $K_{Ca}$ 3.1, causes the cell membrane to become hyperpolarized. Next, this hyperpolarization creates a driving force for  $Ca^{2^+}$  entry into the cell through open  $Ca^{2^+}$  channels on the cell membrane. This influx of  $Ca^{2^+}$  increases the  $[Ca^{2^+}]_i$ , which in turn increases the activity of  $Ca^{2^+}$ -dependent kinases within the cell, including  $Ca^{2^+}$ /calmodulin-dependent kinases. These kinases regulate the activity of cyclins and cyclin-dependent kinases, which not only allow the cell to progress through  $G_1$ , but can also regulate cell cycle progression at various transition checkpoints (Wonderlin and Strobl, 1996; Hartwell *et al.*, 2001).




Figure 20. Schematic model illustrating the mechanisms involved in  $K^+$  channel mediated cell volume regulation in HBE cells. A decrease in extracellular osmolarity activates stretch-activated channels, presumably TRPV4, which causes the influx of  $Ca^{2+}$  into the cell. The increase in  $[Ca^{2+}]_i$  can then activate  $K_{Ca}1.1$  and  $K_{Ca}3.1$  in HBE cells, which expel  $K^+$  ions and cause the RVD response. This efflux of  $K^+$  ions will hyperpolarize the cell membrane, creating the driving force for  $Ca^{2+}$  to enter the cell through open  $Ca^{2+}$  channels. This creates more  $[Ca^{2+}]_i$ , which depolarizes the cell membrane and activate  $K_v$  channels such as  $K_v7.1$  and  $K_v11.1$ , which expel more  $K^+$  ions and contribute to the RVD response (Lang *et al.*, 1996; Fernandez-Fernandez *et al.*, 2002).

#### REFERENCES

- Abbott, G. W., Sesti, F., Splawski, I., Buck, M. E., Lehmann, M. H., Timothy, K. W., et al. (1999). MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. *Cell*, *97*(2), 175-187.
- Agre, P. (2006). The aquaporin water channels. *Proceedings of the American Thoracic Society*, 3(1), 5-13.
- Amberg, G. C., Koh, S. D., Hatton, W. J., Murray, K. J., Monaghan, K., Horowitz, B., et al. (2002). Contribution of Kv4 channels toward the A-type potassium current in murine colonic myocytes. *The Journal of Physiology*, 544(Pt 2), 403-415.
- Arniges, M., Vazquez, E., Fernandez-Fernandez, J. M., & Valverde, M. A. (2004). Swelling-activated Ca2+ entry via TRPV4 channel is defective in cystic fibrosis airway epithelia. *The Journal of Biological Chemistry*, 279(52), 54062-54068.
- Bahring, R., Milligan, C. J., Vardanyan, V., Engeland, B., Young, B. A., Dannenberg, J., et al. (2001). Coupling of voltage-dependent potassium channel inactivation and oxidoreductase active site of kvbeta subunits. *The Journal of Biological Chemistry*, 276(25), 22923-22929.
- Bai, X., Ma, J., Pan, Z., Song, Y. H., Freyberg, S., Yan, Y., et al. (2007). Electrophysiological properties of human adipose tissue-derived stem cells. *American Journal of Physiology, Cell Physiology, 293*(5), C1539-50.
- Bardou, O., Trinh, N. T., & Brochiero, E. (2009). Molecular diversity and function of K+ channels in airway and alveolar epithelial cells. *American Journal of Physiology*. *Lung Cellular and Molecular Physiology*, 296(2), L145-55.
- Barfield, J. P., Yeung, C. H., & Cooper, T. G. (2005). The effects of putative K+ channel blockers on volume regulation of murine spermatozoa. *Biology of Reproduction*, 72(5), 1275-1281.
- Barry, D. M., Xu, H., Schuessler, R. B., & Nerbonne, J. M. (1998). Functional knockout of the transient outward current, long-QT syndrome, and cardiac remodeling in mice expressing a dominant-negative Kv4 alpha subunit. *Circulation Research*, 83(5), 560-567.
- Bauer, C. K., & Schwarz, J. R. (2001). Physiology of EAG K+ channels. *The Journal of Membrane Biology*, 182(1), 1-15.
- Becker, D., Blase, C., Bereiter-Hahn, J., & Jendrach, M. (2005). TRPV4 exhibits a functional role in cell-volume regulation. *Journal of Cell Science*, 118(Pt 11), 2435-2440.

- Beckman Coulter, Inc. (2011). The coulter principle. https://www.beckmancoulter.com/wsrportal/wsr/industrial/particle-technologies/coulter-principle/index.htm.
- Berkefeld, H., Fakler, B., & Schulte, U. (2010). Ca2+-activated K+ channels: From protein complexes to function. *Physiological Reviews*, *90*(4), 1437-1459.
- Berkefeld, H., Sailer, C. A., Bildl, W., Rohde, V., Thumfart, J. O., Eble, S., et al. (2006). BKCa-cav channel complexes mediate rapid and localized Ca2+-activated K+ signaling. *Science (New York, N.Y.)*, 314(5799), 615-620.
- Bernard, K., Bogliolo, S., Soriani, O., & Ehrenfeld, J. (2003). Modulation of calcium-dependent chloride secretion by basolateral SK4-like channels in a human bronchial cell line. *The Journal of Membrane Biology*, 196(1), 15-31.
- Bezanilla, F. (2000). The voltage sensor in voltage-dependent ion channels. *Physiological Reviews*, 80(2), 555-592.
- Bianchi, L., Wible, B., Arcangeli, A., Taglialatela, M., Morra, F., Castaldo, P., et al. (1998). Herg encodes a K+ current highly conserved in tumors of different histogenesis: A selective advantage for cancer cells? *Cancer Research*, *58*(4), 815-822.
- Birnbaum, S. G., Varga, A. W., Yuan, L. L., Anderson, A. E., Sweatt, J. D., & Schrader, L. A. (2004). Structure and function of Kv4-family transient potassium channels. *Physiological Reviews*, 84(3), 803-833.
- Blouquit-Laye, S., & Chinet, T. (2007). Ion and liquid transport across the bronchiolar epithelium. *Respiratory Physiology & Neurobiology*, 159(3), 278-282.
- Borowiec, A. S., Hague, F., Harir, N., Guenin, S., Guerineau, F., Gouilleux, F., et al. (2007). IGF-1 activates hEAG K(+) channels through an akt-dependent signaling pathway in breast cancer cells: Role in cell proliferation. *Journal of Cellular Physiology*, 212(3), 690-701.
- Boxall, C., Holgate, S. T., & Davies, D. E. (2006). The contribution of transforming growth factor-beta and epidermal growth factor signalling to airway remodelling in chronic asthma. *The European Respiratory Journal : Official Journal of the European Society for Clinical Respiratory Physiology, 27*(1), 208-229.
- Brakemeier, S., Kersten, A., Eichler, I., Grgic, I., Zakrzewicz, A., Hopp, H., et al. (2003). Shear stress-induced up-regulation of the intermediate-conductance ca(2+)-activated K(+) channel in human endothelium. *Cardiovascular Research*, 60(3), 488-496.
- Brooks, S. C., & Skafar, D. F. (2004). From ligand structure to biological activity: Modified estratrienes and their estrogenic and antiestrogenic effects in MCF-7 cells. *Steroids*, 69(6), 401-418.

- Busch, A. E., Busch, G. L., Ford, E., Suessbrich, H., Lang, H. J., Greger, R., et al. (1997). The role of the IsK protein in the specific pharmacological properties of the IKs channel complex. *British Journal of Pharmacology*, *122*(2), 187-189.
- Busch, A. E., Herzer, T., Wagner, C. A., Schmidt, F., Raber, G., Waldegger, S., et al. (1994). Positive regulation by chloride channel blockers of IsK channels expressed in xenopus oocytes. *Molecular Pharmacology*, 46(4), 750-753.
- Cavalli, A., Poluzzi, E., De Ponti, F., and Recanatini, M. (2002). Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a coMFA study of herg K+ channel blockers. *Journal of Medicinal Chemistry*, *45*(18), 3844-3853.
- Cherubini, A., Taddei, G. L., Crociani, O., Paglierani, M., Buccoliero, A. M., Fontana, L., et al. (2000). HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. *British Journal of Cancer*, 83(12), 1722-1729.
- Chihara, J., Urayama, O., Tsuda, A., Kakazu, T., Higashimoto, I., and Yamada, H. (1996). Eosinophil cationic protein induces insulin-like growth factor 1 receptor expression on bronchial epithelial cells. *Int Arch Allergy Immunol*, 111(1), 43-45.
- Chilvers, M. A., & O'Callaghan, C. (2000). Local mucociliary defence mechanisms. *Paediatric Respiratory Reviews, 1*(1), 27-34.
- Coakley, R. D., Sun, H., Clunes, L. A., Rasmussen, J. E., Stackhouse, J. R., Okada, S. F., Fricks, I., Young, S. L., and Tarran R. (2008). 17beta-Estradiol inhibits Ca2+dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia. *J Clin Invest*, 118(12), 4025-4035.
- Cowley, E. A., & Linsdell, P. (2002). Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line calu-3. *The Journal of Physiology*, *538*(Pt 3), 747-757.
- Cozens, A. L., Yezzi, M. J., Kunzelmann, K., Ohrui, T., Chin, L., Eng, K., et al. (1994). CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. *American Journal of Respiratory Cell and Molecular Biology*, 10(1), 38-47.
- Cozens, A. L., Yezzi, M. J., Chin, L., Simon, E. M., Finkbeiner, W. E., Wagner, J. A., et al. (1992). Characterization of immortal cystic fibrosis tracheobronchial gland epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, 89(11), 5171-5175.
- Crosby, L. M., & Waters, C. M. (2010). Epithelial repair mechanisms in the lung. American Journal of Physiology. Lung Cellular and Molecular Physiology, 298(6), L715-31.

- Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., & Keating, M. T. (1995). A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. *Cell*, 80(5), 795-803.
- Cuthbert, A. W., Supuran, C. T., & MacVinish, L. J. (2003). Bicarbonate-dependent chloride secretion in calu-3 epithelia in response to 7,8-benzoquinoline. *The Journal of Physiology*, 551(Pt 1), 79-92.
- Cystic Fibrosis Canada. (2011). The Canadian Facts & Figures on Cystic Fibrosis. http://www.cysticfibrosis.ca/en/aboutCysticFibrosis/CfStatistics.php.
- Devor, D. C., Singh, A. K., Lambert, L. C., DeLuca, A., Frizzell, R. A., & Bridges, R. J. (1999). Bicarbonate and chloride secretion in calu-3 human airway epithelial cells. *The Journal of General Physiology*, 113(5), 743-760.
- Devor, D. C., Singh, A. K., Frizzell, R. A., & Bridges, R. J. (1996). Modulation of cl-secretion by benzimidazolones. I. direct activation of a ca(2+)-dependent K+ channel. *The American Journal of Physiology*, 271(5 Pt 1), L775-84.
- Diochot, S., Drici, M. D., Moinier, D., Fink, M., & Lazdunski, M. (1999). Effects of phrixotoxins on the Kv4 family of potassium channels and implications for the role of Ito1 in cardiac electrogenesis. *British Journal of Pharmacology*, *126*(1), 251-263.
- Ehrhardt, C., Collnot, E. M., Baldes, C., Becker, U., Laue, M., Kim, K. J., et al. (2005). Towards an in vitro model of cystic fibrosis small airway epithelium: Characterisation of the human bronchial epithelial cell line CFBE41o-. *Cell and Tissue Research*, 323(3), 405-415.
- Ehrhardt, C., Kneuer, C., Fiegel, J., Hanes, J., Schaefer, U. F., Kim, K. J., et al. (2002). Influence of apical fluid volume on the development of functional intercellular junctions in the human epithelial cell line 16HBE14o-: Implications for the use of this cell line as an in vitro model for bronchial drug absorption studies. *Cell and Tissue Research*, 308(3), 391-400.
- Escoubas, P., Diochot, S., Celerier, M. L., Nakajima, T., & Lazdunski, M. (2002). Novel tarantula toxins for subtypes of voltage-dependent potassium channels in the Kv2 and Kv4 subfamilies. *Molecular Pharmacology*, 62(1), 48-57.
- Faber, E. S., & Sah, P. (2003). Calcium-activated potassium channels: Multiple contributions to neuronal function. *The Neuroscientist: A Review Journal Bringing Neurobiology, Neurology and Psychiatry, 9*(3), 181-194.
- Fernandez-Fernandez, J. M., Andrade, Y. N., Arniges, M., Fernandes, J., Plata, C., Rubio-Moscardo, F., et al. (2008). Functional coupling of TRPV4 cationic channel and large conductance, calcium-dependent potassium channel in human bronchial epithelial cell lines. *Pflugers Archiv : European Journal of Physiology, 457*(1), 149-159.

- Fernandez-Fernandez, J. M., Nobles, M., Currid, A., Vazquez, E., & Valverde, M. A. (2002). Maxi K+ channel mediates regulatory volume decrease response in a human bronchial epithelial cell line. *American Journal of Physiology. Cell Physiology*, 283(6), C1705-14.
- Gadsby, D. C., Vergani, P., & Csanady, L. (2006). The ABC protein turned chloride channel whose failure causes cystic fibrosis. *Nature*, 440(7083), 477-483.
- Ganetzky, B., & Wu, C. F. (1983). Neurogenetic analysis of potassium currents in drosophila: Synergistic effects on neuromuscular transmission in double mutants. *Journal of Neurogenetics*, *I*(1), 17-28.
- Garcia-Ferreiro, R. E., Kerschensteiner, D., Major, F., Monje, F., Stuhmer, W., & Pardo, L. A. (2004). Mechanism of block of hEag1 K+ channels by imipramine and astemizole. *The Journal of General Physiology*, 124(4), 301-317.
- Gerritsen, J. (2000). Host defence mechanisms of the respiratory system. *Paediatric Respiratory Reviews, 1*(2), 128-134.
- Ghanshani, S., Wulff, H., Miller, M. J., Rohm, H., Neben, A., Gutman, G. A., et al. (2000). Up-regulation of the IKCa1 potassium channel during T-cell activation. molecular mechanism and functional consequences. *The Journal of Biological Chemistry*, 275(47), 37137-37149.
- Gospodarowicz, D., Ill, C. R., & Birdwell, C. R. (1977). Effects of fibroblast and epidermal growth factors on ovarian cell proliferation in vitro. I. characterization of the response of granulosa cells to FGF and EGF. *Endocrinology*, 100(4), 1108-1120.
- Gray, J. W., Dolbeare, F., Pallavicini, M. G., Beisker, W., & Waldman, F. (1986). Cell cycle analysis using flow cytometry. *International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine*, 49(2), 237-255.
- Greenwood, I. A., Yeung, S. Y., Hettiarachi, S., Andersson, M., & Baines, D. L. (2009). KCNQ-encoded channels regulate na+ transport across H441 lung epithelial cells. *Pflugers Archiv : European Journal of Physiology, 457*(4), 785-794.
- Harron, S. A., Clarke, C. M., Jones, C. L., Babin-Muise, D., & Cowley, E. A. (2009). Volume regulation in the human airway epithelial cell line calu-3. *Canadian Journal of Physiology and Pharmacology*, 87(5), 337-346.
- Hartwell, L.H., et al. (2001). Physiology or Medicine for 2001 Press Release. http://nobelprize.org/nobel\_prizes/medicine/laureates/2001/press.html.
- Haslam, G., Wyatt, D., & Kitos, P. A. (2000). Estimating the number of viable animal cells in multi-well cultures based on their lactate dehydrogenase activities. *Cytotechnology*, 32(1), 63-75.

- Hazama, A., Fan, H. T., Abdullaev, I., Maeno, E., Tanaka, S., Ando-Akatsuka, Y., et al. (2000). Swelling-activated, cystic fibrosis transmembrane conductance regulator-augmented ATP release and cl- conductances in murine C127 cells. *The Journal of Physiology*, *523 Pt 1*, 1-11.
- Heginbotham, L., Abramson, T., & MacKinnon, R. (1992). A functional connection between the pores of distantly related ion channels as revealed by mutant K+channels. *Science (New York, N.Y.)*, 258(5085), 1152-1155.
- Hemmerlein, B., Weseloh, R. M., Mello de Queiroz, F., Knotgen, H., Sanchez, A., Rubio, M. E., et al. (2006). Overexpression of Eag1 potassium channels in clinical tumours. *Molecular Cancer*, *5*, 41.
- Holland, M., Langton, P. D., Standen, N. B., & Boyle, J. P. (1996). Effects of the BKCa channel activator, NS1619, on rat cerebral artery smooth muscle. *British Journal of Pharmacology*, 117(1), 119-129.
- Ilio, K. Y., Sensibar, J. A., & Lee, C. (1995). Effect of TGF-beta 1, TGF-alpha, and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture. *Journal of Andrology*, 16(6), 482-490.
- Ishii, T. M., Maylie, J., & Adelman, J. P. (1997). Determinants of apamin and d-tubocurarine block in SK potassium channels. *The Journal of Biological Chemistry*, 272(37), 23195-23200.
- Jang, S. H., Choi, C., Hong, S. G., Yarishkin, O. V., Bae, Y. M., Kim, J. G., et al. (2009). Silencing of Kv4.1 potassium channels inhibits cell proliferation of tumorigenic human mammary epithelial cells. *Biochemical and Biophysical Research Communications*, 384(2), 180-186.
- Jensen, B. S., Odum, N., Jorgensen, N. K., Christophersen, P., & Olesen, S. P. (1999). Inhibition of T cell proliferation by selective block of ca(2+)-activated K(+) channels. *Proceedings of the National Academy of Sciences of the United States of America*, 96(19), 10917-10921.
- Jensen, H. S., Callo, K., Jespersen, T., Jensen, B. S., & Olesen, S. P. (2005). The KCNQ5 potassium channel from mouse: A broadly expressed M-current like potassium channel modulated by zinc, pH, and volume changes. *Brain Research. Molecular Brain Research*, 139(1), 52-62.
- Jiang, M., Tseng-Crank, J., & Tseng, G. N. (1997). Suppression of slow delayed rectifier current by a truncated isoform of KvLQT1 cloned from normal human heart. *The Journal of Biological Chemistry*, 272(39), 24109-24112.
- Jiang, Q., & Engelhardt, J. F. (1998). Cellular heterogeneity of CFTR expression and function in the lung: Implications for gene therapy of cystic fibrosis. *European Journal of Human Genetics : EJHG*, 6(1), 12-31.

- Kerem, B., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., et al. (1989). Identification of the cystic fibrosis gene: Genetic analysis. *Science* (*New York, N.Y.*), 245(4922), 1073-1080.
- Kim, H. J., Jang, S. H., Jeong, Y. A., Ryu, P. D., Kim, D. Y., & Lee, S. Y. (2010). Involvement of Kv4.1 K(+) channels in gastric cancer cell proliferation. *Biological & Pharmaceutical Bulletin*, 33(10), 1754-1757.
- Kohler, M., Hirschberg, B., Bond, C. T., Kinzie, J. M., Marrion, N. V., Maylie, J., et al. (1996). Small-conductance, calcium-activated potassium channels from mammalian brain. *Science (New York, N.Y.)*, 273(5282), 1709-1714.
- Kraft, R., Krause, P., Jung, S., Basrai, D., Liebmann, L., Bolz, J., et al. (2003). BK channel openers inhibit migration of human glioma cells. *Pflugers Archiv : European Journal of Physiology*, 446(2), 248-255.
- Kubisch, C., Schroeder, B. C., Friedrich, T., Lutjohann, B., El-Amraoui, A., Marlin, S., et al. (1999). KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. *Cell*, *96*(3), 437-446.
- Kunzelmann, K. (2001). CFTR: Interacting with everything? News in Physiological Sciences: An International Journal of Physiology Produced Jointly by the International Union of Physiological Sciences and the American Physiological Society, 16, 167-170.
- Lang, F., Busch, G. L., Ritter, M., Volkl, H., Waldegger, S., Gulbins, E., et al. (1998). Functional significance of cell volume regulatory mechanisms. *Physiological Reviews*, 78(1), 247-306.
- Lee, S. Y., Maniak, P. J., Ingbar, D. H., & O'Grady, S. M. (2003). Adult alveolar epithelial cells express multiple subtypes of voltage-gated K+ channels that are located in apical membrane. *American Journal of Physiology. Cell Physiology*, 284(6), C1614-24.
- Lerche, C., Scherer, C. R., Seebohm, G., Derst, C., Wei, A. D., Busch, A. E., et al. (2000). Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity. *The Journal of Biological Chemistry*, 275(29), 22395-22400.
- Lock, H., & Valverde, M. A. (2000). Contribution of the IsK (MinK) potassium channel subunit to regulatory volume decrease in murine tracheal epithelial cells. *The Journal of Biological Chemistry*, 275(45), 34849-34852.
- Magleby, K. L. (2003). Gating mechanism of BK (Slo1) channels: So near, yet so far. *The Journal of General Physiology, 121*(2), 81-96.

- Mall, M., Wissner, A., Schreiber, R., Kuehr, J., Seydewitz, H. H., Brandis, M., et al. (2000). Role of K(V)LQT1 in cyclic adenosine monophosphate-mediated cl(-) secretion in human airway epithelia. *American Journal of Respiratory Cell and Molecular Biology*, 23(3), 283-289.
- Manikkam, M., Li, Y., Mitchell, B. M., Mason, D. E., & Freeman, L. C. (2002). Potassium channel antagonists influence porcine granulosa cell proliferation, differentiation, and apoptosis. *Biology of Reproduction*, 67(1), 88-98.
- McDonald, T. V., Yu, Z., Ming, Z., Palma, E., Meyers, M. B., Wang, K. W., et al. (1997). A minK-HERG complex regulates the cardiac potassium current I(kr). *Nature*, 388(6639), 289-292.
- McKay, M. C., Dworetzky, S. I., Meanwell, N. A., Olesen, S. P., Reinhart, P. H., Levitan, I. B., et al. (1994). Opening of large-conductance calcium-activated potassium channels by the substituted benzimidazolone NS004. *Journal of Neurophysiology*, 71(5), 1873-1882.
- Meera, P., Wallner, M., Song, M., & Toro, L. (1997). Large conductance voltage- and calcium-dependent K+ channel, a distinct member of voltage-dependent ion channels with seven N-terminal transmembrane segments (S0-S6), an extracellular N terminus, and an intracellular (S9-S10) C terminus. *Proceedings of the National Academy of Sciences of the United States of America*, 94(25), 14066-14071.
- Meyer, R., Schonherr, R., Gavrilova-Ruch, O., Wohlrab, W., & Heinemann, S. H. (1999). Identification of ether a go-go and calcium-activated potassium channels in human melanoma cells. *The Journal of Membrane Biology*, 171(2), 107-115.
- Mongin, A. A., & Orlov, S. N. (2001). Mechanisms of cell volume regulation and possible nature of the cell volume sensor. *Pathophysiology: The Official Journal of the International Society for Pathophysiology / ISP*, 8(2), 77-88.
- Moser, S. L., Harron, S. A., Crack, J., Fawcett, J. P., & Cowley, E. A. (2008). Multiple KCNQ potassium channel subtypes mediate basal anion secretion from the human airway epithelial cell line calu-3. *The Journal of Membrane Biology*, *221*(3), 153-163.
- Muth, T. R., & Caplan, M. J. (2003). Transport protein trafficking in polarized cells. *Annual Review of Cell and Developmental Biology*, 19, 333-366.
- Namkung, W., Song, Y., Mills, A.D., Padmawar, P., Finkbeiner, W.E., and Verkman, A.S. (2009). In situ measurement of airway surface liquid [K] using a ratioable K-sensitive fluorescent dye. *The Journal of Biological Chemistry*, 284(23), 15916-15926.
- NIH Chemical Genomic Center. (2009). Section 12: Setting up a cell proliferation assay. http://assay.nih.gov/assay/index.php/Section12:Setting\_Up\_a\_Cell\_Proliferation\_ Assay#Determine\_the\_Doubling\_Time\_of\_the\_Cells

- Occhiodoro, T., Bernheim, L., Liu, J. H., Bijlenga, P., Sinnreich, M., Bader, C. R., et al. (1998). Cloning of a human ether-a-go-go potassium channel expressed in myoblasts at the onset of fusion. *FEBS Letters*, 434(1-2), 177-182.
- O'Grady, S. M., & Lee, S. Y. (2003). Chloride and potassium channel function in alveolar epithelial cells. *American Journal of Physiology. Lung Cellular and Molecular Physiology*, 284(5), L689-700.
- Ouadid-Ahidouch, H., Roudbaraki, M., Ahidouch, A., Delcourt, P., & Prevarskaya, N. (2004). Cell-cycle-dependent expression of the large Ca2+-activated K+ channels in breast cancer cells. *Biochemical and Biophysical Research Communications*, *316*(1), 244-251.
- Ouadid-Ahidouch, H., Le Bourhis, X., Roudbaraki, M., Toillon, R. A., Delcourt, P., & Prevarskaya, N. (2001). Changes in the K+ current-density of MCF-7 cells during progression through the cell cycle: Possible involvement of a h-ether.a-gogo K+ channel. *Receptors & Channels*, 7(5), 345-356.
- Ousingsawat, J., Spitzner, M., Puntheeranurak, S., Terracciano, L., Tornillo, L., Bubendorf, L., et al. (2007). Expression of voltage-gated potassium channels in human and mouse colonic carcinoma. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*, 13(3), 824-831.
- Pantazis, A., Gudzenko, V., Savalli, N., Sigg, D., & Olcese, R. (2010). Operation of the voltage sensor of a human voltage- and Ca2+-activated K+ channel. *Proceedings of the National Academy of Sciences of the United States of America*, 107(9), 4459-4464.
- Pardo, L. A., del Camino, D., Sanchez, A., Alves, F., Bruggemann, A., Beckh, S., et al. (1999). Oncogenic potential of EAG K(+) channels. *The EMBO Journal*, 18(20), 5540-5547.
- Pluteanu, F., & Cribbs, L. L. (2011). Regulation and function of Cav3.1 T-type calcium channels in IGF-I-stimulated pulmonary artery smooth muscle cells. *American Journal of Physiology. Cell Physiology*, 300(3), C517-25.
- Pluznick, J. L., & Sansom, S. C. (2006). BK channels in the kidney: Role in K(+) secretion and localization of molecular components. *American Journal of Physiology. Renal Physiology, 291*(3), F517-29.
- Pongs, O. (1992). Structural basis of voltage-gated K+ channel pharmacology. *Trends in Pharmacological Sciences*, 13(9), 359-365.
- Rahman, F. B., Ishihara, S., Aziz, M. M., Mishima, Y., Oshima, N., Li, Y. Y., et al. (2010). Heparin-binding EGF-like factor augments esophageal epithelial cell proliferation, migration and inhibits TRAIL-mediated apoptosis via EGFR/MAPK signaling. *Scandinavian Journal of Gastroenterology*, *45*(11), 1350-1359.

- Reinlib, L., Jefferson, D. J., Marini, F. C., & Donowitz, M. (1992). Abnormal secretagogue-induced intracellular free Ca2+ regulation in cystic fibrosis nasal epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, 89(7), 2955-2959.
- Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. *Science (New York, N.Y.)*, 245(4922), 1066-1073.
- Robbins, J. (2001). KCNQ potassium channels: Physiology, pathophysiology, and pharmacology. *Pharmacology & Therapeutics*, 90(1), 1-19.
- Rosati, B., Marchetti, P., Crociani, O., Lecchi, M., Lupi, R., Arcangeli, A., et al. (2000). Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: The role of HERG K(+) channels in firing and release. *The FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 14*(15), 2601-2610.
- Roura-Ferrer, M., Sole, L., Martinez-Marmol, R., Villalonga, N., & Felipe, A. (2008). Skeletal muscle Kv7 (KCNQ) channels in myoblast differentiation and proliferation. *Biochemical and Biophysical Research Communications*, *369*(4), 1094-1097.
- Roy, J. W., Cowley, E. A., Blay, J., & Linsdell, P. (2010). The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. *British Journal of Pharmacology*, 159(3), 650-658.
- Roy, J., Vantol, B., Cowley, E. A., Blay, J., & Linsdell, P. (2008). Pharmacological separation of hEAG and hERG K+ channel function in the human mammary carcinoma cell line MCF-7. *Oncology Reports*, 19(6), 1511-1516.
- Sah, P. (1996). Ca(2+)-activated K+ currents in neurones: Types, physiological roles and modulation. *Trends in Neurosciences*, 19(4), 150-154.
- Salkoff, L., Butler, A., Ferreira, G., Santi, C., & Wei, A. (2006). High-conductance potassium channels of the SLO family. *Nature Reviews.Neuroscience*, 7(12), 921-931.
- Sanguinetti, M. C., Johnson, J. H., Hammerland, L. G., Kelbaugh, P. R., Volkmann, R. A., Saccomano, N. A., et al. (1997). Heteropodatoxins: Peptides isolated from spider venom that block Kv4.2 potassium channels. *Molecular Pharmacology*, 51(3), 491-498.
- Sanguinetti, M. C., Curran, M. E., Zou, A., Shen, J., Spector, P. S., Atkinson, D. L., et al. (1996). Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(ks) potassium channel. *Nature*, 384(6604), 80-83.

- Sanguinetti, M. C., Jiang, C., Curran, M. E., & Keating, M. T. (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. *Cell*, *81*(2), 299-307.
- Sanguinetti, M. C., & Jurkiewicz, N. K. (1990). Two components of cardiac delayed rectifier K+ current. differential sensitivity to block by class III antiarrhythmic agents. *The Journal of General Physiology*, *96*(1), 195-215.
- Scaloni, A., Bottiglieri, C., Ferrara, L., Corona, M., Gurrola, G. B., Batista, C., et al. (2000). Disulfide bridges of ergtoxin, a member of a new sub-family of peptide blockers of the ether-a-go-go-related K+ channel. *FEBS Letters*, 479(3), 156-157.
- Schwiebert, E. M., Benos, D. J., Egan, M. E., Stutts, M. J., & Guggino, W. B. (1999). CFTR is a conductance regulator as well as a chloride channel. *Physiological Reviews*, 79(1 Suppl), S145-66.
- Sleigh, M. A., Blake, J. R., & Liron, N. (1988). The propulsion of mucus by cilia. *The American Review of Respiratory Disease*, 137(3), 726-741.
- Smith, G. A., Tsui, H. W., Newell, E. W., Jiang, X., Zhu, X. P., Tsui, F. W., et al. (2002). Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. *The Journal of Biological Chemistry*, 277(21), 18528-18534.
- Smith, P. L., & Frizzell, R. A. (1984). Chloride secretion by canine tracheal epithelium: IV. basolateral membrane K permeability parallels secretion rate. *The Journal of Membrane Biology*, 77(3), 187-199.
- Stocker, M. (2004). Ca(2+)-activated K+ channels: Molecular determinants and function of the SK family. *Nature Reviews.Neuroscience*, *5*(10), 758-770.
- Strobaek, D., Christophersen, P., Holm, N. R., Moldt, P., Ahring, P. K., Johansen, T. E., et al. (1996). Modulation of the ca(2+)-dependent K+ channel, hslo, by the substituted diphenylurea NS 1608, paxilline and internal Ca2+. *Neuropharmacology*, *35*(7), 903-914.
- Trinh, N. T., Prive, A., Maille, E., Noel, J., & Brochiero, E. (2008). EGF and K+ channel activity control normal and cystic fibrosis bronchial epithelia repair. *American Journal of Physiology. Lung Cellular and Molecular Physiology*, 295(5), L866-80.
- Trinh, N. T., Prive, A., Kheir, L., Bourret, J. C., Hijazi, T., Amraei, M. G., et al. (2007). Involvement of KATP and KvLQT1 K+ channels in EGF-stimulated alveolar epithelial cell repair processes. *American Journal of Physiology. Lung Cellular and Molecular Physiology*, 293(4), L870-82.
- vanTol, B. L., Missan, S., Crack, J., Moser, S., Baldridge, W. H., Linsdell, P., et al. (2007). Contribution of KCNQ1 to the regulatory volume decrease in the human mammary epithelial cell line MCF-7. *American Journal of Physiology. Cell Physiology*, 293(3), C1010-9.

- Vazquez, E., Nobles, M., & Valverde, M. A. (2001). Defective regulatory volume decrease in human cystic fibrosis tracheal cells because of altered regulation of intermediate conductance Ca2+-dependent potassium channels. *Proceedings of the National Academy of Sciences of the United States of America*, 98(9), 5329-5334.
- Vergara, C., Latorre, R., Marrion, N. V., & Adelman, J. P. (1998). Calcium-activated potassium channels. *Current Opinion in Neurobiology*, 8(3), 321-329.
- Wang, H., Zhang, Y., Cao, L., Han, H., Wang, J., Yang, B., et al. (2002a). HERG K+channel, a regulator of tumor cell apoptosis and proliferation. *Cancer Research*, 62(17), 4843-4848.
- Wang, H. S., Brown, B. S., McKinnon, D., and Cohen, I. S. (2000). Molecular basis for differential sensitivity of KCNQ and IKs channels to the cognitive enhancer XE991. *Mol Pharmacol*, *57*(6), 1218-1223.
- Wang, H. S., Pan, Z., Shi, W., Brown, B. S., Wymore, R. S., Cohen, I. S., et al. (1998). KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel. *Science (New York, N.Y.)*, 282(5395), 1890-1893.
- Wang, L., Chen, L., Zhu, L., Rawle, M., Nie, S., Zhang, J., et al. (2002b). Regulatory volume decrease is actively modulated during the cell cycle. *Journal of Cellular Physiology*, 193(1), 110-119.
- Wang, Q., Curran, M. E., Splawski, I., Burn, T. C., Millholland, J. M., VanRaay, T. J., et al. (1996). Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. *Nature Genetics*, 12(1), 17-23.
- Ward, C. L., Omura, S., & Kopito, R. R. (1995). Degradation of CFTR by the ubiquitin-proteasome pathway. *Cell*, 83(1), 121-127.
- Warth, R., Riedemann, N., Bleich, M., Van Driessche, W., Busch, A. E., & Greger, R. (1996). The cAMP-regulated and 293B-inhibited K+ conductance of rat colonic crypt base cells. *Pflugers Archiv : European Journal of Physiology, 432*(1), 81-88.
- Wei, A. D., Gutman, G. A., Aldrich, R., Chandy, K. G., Grissmer, S., & Wulff, H. (2005). International union of pharmacology. LII. nomenclature and molecular relationships of calcium-activated potassium channels. *Pharmacological Reviews*, 57(4), 463-472.
- Williams, S. E., Wootton, P., Mason, H. S., Bould, J., Iles, D. E., Riccardi, D., et al. (2004). Hemoxygenase-2 is an oxygen sensor for a calcium-sensitive potassium channel. *Science (New York, N.Y.)*, 306(5704), 2093-2097.
- Wills, N. K., Reuss, L., and Lewis S.A. (1996). Epithelial structure and function. In: Epithelial Transport: A guide to methods and experimental analysis. First edition. Chapman & Hall, London.

- Wolterbeek, H. T., & van der Meer, A. J. (2005). Optimization, application, and interpretation of lactate dehydrogenase measurements in microwell determination of cell number and toxicity. *Assay and Drug Development Technologies*, *3*(6), 675-682.
- Wonderlin, W. F., & Strobl, J. S. (1996). Potassium channels, proliferation and G1 progression. *The Journal of Membrane Biology*, 154(2), 91-107.
- Xia, X. M., Fakler, B., Rivard, A., Wayman, G., Johnson-Pais, T., Keen, J. E., et al. (1998). Mechanism of calcium gating in small-conductance calcium-activated potassium channels. *Nature*, *395*(6701), 503-507.
- Yao, J. A., Du, X., Lu, D., Baker, R. L., Daharsh, E., & Atterson, P. (2005). Estimation of potency of HERG channel blockers: Impact of voltage protocol and temperature. *Journal of Pharmacological and Toxicological Methods*, *52*(1), 146-153.
- Yeung, S. Y., Pucovsky, V., Moffatt, J. D., Saldanha, L., Schwake, M., Ohya, S., et al. (2007). Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. *British Journal of Pharmacology*, 151(6), 758-770.
- Zaczek, R., Chorvat, R. J., Saye, J. A., Pierdomenico, M. E., Maciag, C. M., Logue, A. R., et al. (1998). Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: Comparison to linopirdine. *The Journal of Pharmacology and Experimental Therapeutics*, 285(2), 724-730.
- Zeuthen, T. (1994). Cotransport of K+, cl- and H2O by membrane proteins from choroid plexus epithelium of necturus maculosus. *The Journal of Physiology, 478 (Pt 2)*(Pt 2), 203-219.
- Zhu, Y., Golden, C. M., Ye, J., Wang, X. Y., Akbarali, H. I., & Huizinga, J. D. (2003). ERG K+ currents regulate pacemaker activity in ICC. *American Journal of Physiology, Gastrointestinal and Liver Physiology*, 285(6), G1249-58.

## **APPENDIX A: TABLES**

Table 1. K<sup>+</sup> channel name and their corresponding gene name.

Channel Name	Gene Name
K <sub>v</sub> 7.1	KCNQ1
K <sub>v</sub> 7.5	KCNQ5
K <sub>v</sub> 4.1	KCND1
K <sub>v</sub> 4.2	KCND2
K <sub>v</sub> 4.3	KCND3
K <sub>v</sub> 10.1	KCNH1
K <sub>v</sub> 11.1	KCNH2
K <sub>Ca</sub> 1.1	KCNMA1
K <sub>Ca</sub> 3.1	KCNN4

Table 2. K<sup>+</sup> channel inhibitors and information.

Drug Name	le 2. K <sup>+</sup> channel inhibitors and information. ug Name   Channels   Vehicle   Stock [C]   IC <sub>50</sub> value				
	Inhibited		[-]	50 111 1	Company
XE991	K <sub>v</sub> 7.1-7.5	H <sub>2</sub> O	100 mM	0.6-1 μM (Tocris)	Tocris Bioscience
Chromanol 293B	K <sub>v</sub> 7.1	Dimethyl Sulfoxide (DMSO)	100 mM	1-10 μM (Tocris)	Tocris Bioscience
Flecainide	K <sub>v</sub> 4.1-4.3	Methanol	50 mM	11-100 µM (Barfield <i>et al.</i> , 2005; Amberg <i>et al.</i> , 2002)	Sigma- Aldrich
Stromatoxin	K <sub>v</sub> 4.2	H <sub>2</sub> O	20 μΜ	1.2 nM (Escoubas <i>et al.</i> , 2002)	Sigma- Aldrich
Astemizole	K <sub>v</sub> 10.1	DMSO	100 mM	200 nM (Garcia- Ferreiro <i>et</i> <i>al.</i> , 2004)	Sigma- Aldrich
E-4031	K <sub>v</sub> 11.1	H <sub>2</sub> O	2 mM	14 nM (Yao et al., 2005)	Sigma- Aldrich
Paxilline	K <sub>Ca</sub> 1.1	Chloroform	10 mM	1.9 nM (Tocris)	Sigma- Aldrich
TRAM-34	K <sub>Ca</sub> 3.1	DMSO	14.5 mM	20 nM (Tocris)	Sigma- Aldrich

Table 3. PCR primer sequences and information.

i able 3. P	CR primer sequences and information.	T	_	
Channel Name	Primer Sequences	Annealing Temp (°C)	Base Pair Size (bp)	Reference
	Forward			
$K_{v}7.1$	5'-CTTGCCATCTCTTCTTG-3'	HBE: 56	411	Moser et
120 / . 1	Reverse	CFBE: 60		al., 2008
	5'-AGTGTTGGGCTCTTCCTTAC-3'	CIBE. 00		<i>an.</i> , 2000
	Forward			
$K_v 7.5$	5'-CGCTTTCGTTTTCTCCTTG-3'	HBE: 59	207	Moser et
$\mathbf{K}_{V}$ / . $\mathcal{S}$	Reverse	CFBE: 60	207	al., 2008
	5'-CGAGCAAACCTCAGTCTTCC-3'	CIBE. 00		<i>ui.</i> , 2008
TZ 4 1				
$K_v4.1$	Forward	HDE 65	225	D : 1
	5'-CCACTTGCTGCAGTGTCTAG-3'	HBE: 65	335	Bai et al.,
	Reverse	CFBE: 65		2007
	5'-TGTCGCAGTTCAGGTCAAGG-3'			
	Forward			
$K_v4.2$	5'-ATCTTCCGCCACATCCTGAA-3'	HBE: 59	362	Bai et al.,
	Reverse	CFBE: 59		2007
	5'-GATCCGCACGGCACTGTTTC-3'			
	Forward			
$K_v4.3$	5'-GATGAGCAGATGTTTGAGCAG-3'	Calu-3: 60	106	Bai et al.,
•	Reverse			2007
	5'-AGCAGGTGGTAGTGAGGCC-3'			
	Forward			
$K_{v}10.1$	5'-CGCATGAACTACCTGAAGACG-3'	CFBE: 60	479	Borowiec
11,10.1	Reverse	CIBE: 00	177	et al., 2007
	5'-TCTGTGGATGGGGCGATGTTC-3'			Ci ui., 2007
	Forward			
K <sub>v</sub> 11.1	5'-ATGTGACGGCGCTCTACTTC-3'	HBE: 60	172	Roy et al.,
$\mathbf{K}_{V}$ 11.1	Reverse	CFBE: 60	1/2	2008
		CFBE. 00		2008
	5'-GAGTACAGCCGCTGGATGAT-3'			
T7 1 1	Forward	HDE (0	1.50	D . 1
$K_{Ca}1.1$	5'-GGAATGGGAGACGCTTCATA-3'	HBE: 60	153	Roy et al.,
	Reverse	CFBE: 60		2009
	5'-CCTGCAGCGAAGTATCATCA-3'			
	Forward		1	
$K_{Ca}3.1$	5'-CATCACATTCCTGACCATCG-3'	HBE: 60	158	Brakemei
Ca= • •	Reverse	CFBE: 60		et al., 2003
	5'-ACGTGCTTCTCTGCCTTGTT-3'			2003
	Forward			
HPRT	5'-GCCAGACTTTGTTGGATTTG-3'	HBE: 60	141	Doy at al
пгкі			141	Roy et al.,
	Reverse	CFBE: 60		2006
	5'-CTCTCATCTTAGGCTTTGTATTTTG-3'			

**Table 4. Antibody information.** 

Antibody	Channel Name	Protein Size (kDa)	Host	Dilution	Company
Primary (1°)	K <sub>v</sub> 7.1	75	Rabbit	1:500	Santa Cruz Biotechnology, INC.
	K <sub>v</sub> 7.5	116	Rabbit	1:2000	Millipore
Secondary (2°)	Anti-Rabbit IgG	N/A	Goat	1:2000	Cell Signaling Technology

#### APPENDIX B: RECIPES

## Fibronectin coating solution (100 mL)

97.8 mL LHC basal medium 0.2 mL BSA (1 mg/ml)

1 mL Vitrogen 100

1 mL Human fibronectin (1mg/ml)

#### Hyperosmotic bath solution (1 L)

4.383 g NaCl

0.186 g KCl

0.176 g CaCl2

0.1016 g MgCl2

0.901 g Glucose

2.383 g Hepes

Mannitol varies for different osmolarities

900 mL ddH<sub>2</sub>O

Stir until completely dissolved

Bring up to 1 L with ddH<sub>2</sub>O; pH to 7.4

#### Hyposmotic bath solution (1 L)

4.383 g NaCl

0.186 g KCl

0.176 g CaCl2

0.1016 g MgCl2

0.901 g Glucose

2.383 g Hepes

Mannitol varies for different osmolarities

900 mL ddH<sub>2</sub>O

Stir until completely dissolved

Bring up to 1 L with ddH<sub>2</sub>O; pH to 7.4

#### Isosmotic bath solution (1 L)

4.383 g NaCl

0.186 g KCl

0.176 g CaCl2

0.1016 g MgCl2

0.901 g Glucose

2.383 g Hepes

27.32 g Mannitol

900 mL ddH<sub>2</sub>O

Stir until completely dissolved

Bring up to 1 L with ddH<sub>2</sub>O; pH to 7.4

#### Phosphate buffered saline (PBS) (10X, 1 L)

13.40 g Na<sub>2</sub>HPO<sub>4</sub>•7H<sub>2</sub>O

8.0 g NaCl

0.2 g KCl

 $0.24 \text{ g KH}_2PO_4$ 

 $900 \text{ mL } ddH_2O$ 

Stir until completely dissolved

Bring up to 1 L with ddH<sub>2</sub>O; pH to 7.4

#### Resolving gel (7.5%, 1 gel)

3.575 mL ddH<sub>2</sub>O

1.875 mL 30% Acyrlamide mix

1.9 mL 1.5 M Tris (pH 8.8)

0.075 mL 10% SDS

0.075 mL 10% APS

0.006 mL TEMED

Add APS and TEMED immediately before pouring the gel

#### RIPA buffer

4 mg Deoxycholic acid

5 mL Triton-X-100

5 mL SDS

4.38 g NaCl

12 mL 1mM EDTA

0.606 g Tris-HCl

Stir until completely dissolved; pH to 7.4

#### Running buffer (10X, I L)

 $700 \text{ mL } ddH_2O$ 

144 g Glycine

30.3 g Tris base

10 g 1% SDS

Stir until completely dissolved; bring up to 1 L with ddH<sub>2</sub>O

#### Stacking gel (5%, 1 gel)

 $3.35 \text{ mL } ddH_2O$ 

1.0 mL 30% Acyrlamide mix

1.5 mL 0.5 M Tris (pH 6.8)

0.060 mL 10% SDS

0.060 mL 10% APS

0.006 mL TEMED

Add APS and TEMED immediately before pouring the gel

## TBS (10X, 1 L)

700 mL ddH<sub>2</sub>O 292.2 g NaCl 24.22 g Tris base Bring up to 1 L with ddH<sub>2</sub>O

### **TBS-T (1 L)**

100 mL 10X TBS 890 mL ddH<sub>2</sub>O 10 mL 10% Tween

### Transfer buffer (10X, 1 L)

700 mL ddH<sub>2</sub>O 144 g Glycine 30.3 g Tris base 1.0 g 1% SDS Stir until completely dissolved; bring up to 1 L with ddH<sub>2</sub>O

### Tris boric acid EDTA (TBE) (10X, 1 L)

108 g Tris base 55 g Boric acid 40 mL 0.5M EDTA 800 mL ddH<sub>2</sub>O Stir until completely dissolved Bring up to 1 L with ddH<sub>2</sub>O